ticlopidine has been researched along with Angina, Unstable in 243 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Angina, Unstable: Precordial pain at rest, which may precede a MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although non-coronary artery bypass graft (CABG) TIMI major bleeding was increased with prasugrel as compared with clopidogrel (HR 1." | 9.19 | Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. ( De Servi, S; Goedicke, J; Schirmer, A; Widimsky, P, 2014) |
| " Patients with non-ST-elevation acute coronary syndrome who were selected for management without [corrected] revascularisation were randomly assigned to clopidogrel or prasugrel." | 9.17 | Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. ( Armstrong, PW; Bhatt, DL; Boden, WE; Clemmensen, P; Fox, KA; Hafley, G; Hamm, C; Leiva-Pons, J; Lokhnygina, Y; Menozzi, A; Nicolau, JC; Ohman, EM; Oto, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; White, HD; Widimsky, P; Winters, KJ; Wiviott, SD, 2013) |
| "Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed." | 9.16 | Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ, 2012) |
| "We studied 13 608 patients with acute coronary syndrome undergoing percutaneous coronary intervention randomized to prasugrel or clopidogrel and treated for 6 to 15 months in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI 38)." | 9.14 | Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi ( Antman, EM; Bonaca, MP; Bramucci, E; Braunwald, E; McCabe, CH; Morrow, DA; Murphy, SA; Nicolau, JC; Ruff, CT; Scirica, BM; White, HD; Wiviott, SD, 2009) |
| " Among a high-risk NSTEMI population not undergoing PCI within 24 hours of arrival, the nonrandomized short-term use of clopidogrel is associated with a lower risk of inhospital mortality without an increased risk of major bleeding." | 9.13 | Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Su ( Alexander, D; Brown, DL; Cannon, CP; Fintel, DJ; Gibler, WB; Ohman, EM; Ou, FS; Peterson, ED; Pollack, CV; Roe, MT, 2008) |
| " The aim of the study was to assess the impact of clopidogrel on safety and efficacy in patients with renal dysfunction in non-ST elevation acute coronary syndromes." | 9.12 | Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. ( Hawken, S; Keltai, M; Lewis, BS; Mann, JF; Mehta, SR; Sitkei, E; Tonelli, M; Yusuf, S, 2007) |
| " The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial demonstrated the effectiveness of clopidogrel plus acetylsalicylic acid (ASA) compared with ASA alone in reducing cardiovascular events in patients with acute coronary syndromes and, in addition, patients undergoing percutaneous coronary intervention in the Percutaneous Coronary Intervention in CURE (PCI-CURE) trial." | 9.12 | Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial. ( Kolm, P; Mehta, SR; O'Brien, JA; Veledar, E; Weintraub, WS; Yuan, Y, 2007) |
| "In patients with NSTE-ACS undergoing early invasive strategy, the adjunctive administration of upstream tirofiban did not reduce the peak values and the cumulative release of myocardial necrosis markers, compared with aspirin, heparin, and clopidogrel given on admission and associated with selective use of abciximab just before PCI." | 9.11 | Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstrea ( Badia, T; Bellandi, F; Dabizzi, RP; De Servi, S; Leoncini, M; Maioli, M; Politi, A; Toso, A, 2005) |
| "We studied the benefits and risks of adding clopidogrel to different doses of aspirin in the treatment of patients with acute coronary syndrome (ACS)." | 9.10 | Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. ( Commerford, PJ; Diaz, R; Fox, KA; Kopecky, SL; Lewis, BS; Mehta, SR; Peters, RJ; Valentin, V; Yusuf, S; Zhao, F, 2003) |
| "Data collected to investigate the effects of ticlopidine in a subset of 489 patients with angina at rest accompanied by transient ischaemic electrocardiographic changes have been analysed." | 9.07 | Ticlopidine treatment for patients with unstable angina at rest. A further analysis of the study of ticlopidine in unstable angina. Studio della Ticlopidina nell'Angina Instabile Group. ( Lagioia, R; Rizzon, P; Scrutinio, D, 1991) |
| " This article reviews the mechanism of action and the major evidence supporting the clinical use of clopidogrel, a potent antiplatelet agent of the thienopyridines class, focusing on its role in the setting of acute coronary syndromes without persistent ST segment elevation (unstable angina and non-Q wave myocardial infarction)." | 8.82 | Clopidogrel in acute coronary syndromes (unstable angina and non-Q-wave myocardial infarction). ( Heras, M; Sionis, A, 2003) |
| "This study sought to examine the effectiveness of clopidogrel in real-world, medically managed patients with unstable angina (UA) or non-ST-segment elevation myocardial infarction (NSTEMI)." | 7.80 | Comparative effectiveness of clopidogrel in medically managed patients with unstable angina and non-ST-segment elevation myocardial infarction. ( Boothroyd, DB; Chang, TI; Go, AS; Hlatky, MA; Kazi, DS; Leong, TK; Shilane, D; Solomon, MD, 2014) |
| "One-year treatment with clopidogrel in addition to aspirin is a cost-effective treatment option for secondary prevention in patients with acute coronary syndrome without ST-segment elevation in Greece." | 7.78 | Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis. ( Fragoulakis, V; Kourlaba, G; Maniadakis, N, 2012) |
| "Recent studies have suggested that low-dose aspirin has preserved benefit with less bleeding compared with standard-dose aspirin when given with or without clopidogrel in patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACSs)." | 7.74 | Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative. ( Cannon, CP; Gibler, WB; Milford-Beland, S; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Tickoo, S, 2007) |
| "Clopidogrel added to aspirin improved outcomes after hospitalization in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) in the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial, regardless of in-hospital treatment approach." | 7.73 | Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. ( Bhatt, DL; Cannon, CP; Fintel, DJ; Gibler, WB; Harrington, RA; Mulgund, J; Newby, LK; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Smith, SC; Tricoci, P, 2006) |
| "We sought to characterize patterns of clopidogrel use before coronary artery bypass grafting (CABG) and examine the drug's impact on risks for postoperative transfusions among patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS)." | 7.73 | Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. ( Cannon, CP; Ferguson, TB; Gibler, WB; Mehta, RH; Mulgund, J; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Smith, SC, 2006) |
| " 178 consecutive patients admitted for acute coronary syndrome received 250 mg of intravenous aspirin together with either a loading dose of 300 mg of clopidogrel (n = 104) or 600 mg (n = 74) administered 12 to 24 hours prior to coronary angiography." | 7.73 | [Beneficial effect of a loading dose of 600 mg of clopidogrel on platelet parameters in patients admitted for acute coronary syndrome]. ( Alessi, MC; Bonnet, JL; Carvajal, J; Cuisset, T; Frère, C; Lambert, M; Morange, PE; Mouret, JP; Quilici, J; Saidi, LN, 2006) |
| "Clopidogrel given for up to 1 year in patients undergoing PCI after presentation with acute coronary syndromes is a highly cost-effective treatment strategy." | 7.73 | Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. ( Caro, J; Chen, R; Culler, S; Gabriel, S; Jackson, J; Lamy, A; Mahoney, EM; Mehta, S; Weintraub, WS; Yuan, Y; Yusuf, S, 2006) |
| "The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study showed that patients with unstable angina pectoris (UAP) and non-ST-elevation myocardial infarction (NSTEMI) benefit from combined therapy with acetylsalicylic acid (ASA) and clopidogrel." | 7.73 | [Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome]. ( Kjaer, J; Larsen, CH; Mickley, H; Møller, JE; Poulsen, TS, 2006) |
| "In the ASCET study, 1000 patients with documented coronary heart disease will be randomized to either continued treatment with aspirin 160 mg/d or change to clopidogrel 75 mg/d after initial determination of their platelet reactivity while on aspirin treatment." | 7.72 | Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. ( Abdelnoor, M; Arnesen, H; Pettersen, AA; Seljeflot, I, 2004) |
| "We report a case of a 76-year-old-man who developed spontaneous hemarthrosis of his right knee following clopidogrel-aspirin treatment." | 7.72 | Spontaneous hemarthrosis of the knee associated with clopidogrel and aspirin treatment. ( Behrens, P; Bernotat, J; Böhm, S; Gille, J; Löhr, JF, 2003) |
| " The CURE trial shows that clopidogrel in addition to aspirin achieves this double goal, with a 20% relative risk reduction in the primary composite endpoint of cardiovascular death, myocardial infarction or stroke in the first 30 days." | 7.71 | [Clopidogrel in acute coronary syndromes with non-ST elevation. Clinical implications of the CURE trial]. ( Valentín, V, 2001) |
| "When ticlopidine was given for 72 hours, TF levels were similar to normal laboratory values both in stable and unstable patients." | 6.69 | Effect of aspirin and ticlopidine on plasma tissue factor levels in stable and unstable angina pectoris. ( Ariëns, RA; Bernies, M; Bossi, IM; Brambilla, GM; Donatelli, F; Fajadet, J; Gregorini, L; Marco, I; Marco, J; Mari, D; Romano, SM; Somalvico, F, 2000) |
| " Although non-coronary artery bypass graft (CABG) TIMI major bleeding was increased with prasugrel as compared with clopidogrel (HR 1." | 5.19 | Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. ( De Servi, S; Goedicke, J; Schirmer, A; Widimsky, P, 2014) |
| " Patients with non-ST-elevation acute coronary syndrome who were selected for management without [corrected] revascularisation were randomly assigned to clopidogrel or prasugrel." | 5.17 | Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. ( Armstrong, PW; Bhatt, DL; Boden, WE; Clemmensen, P; Fox, KA; Hafley, G; Hamm, C; Leiva-Pons, J; Lokhnygina, Y; Menozzi, A; Nicolau, JC; Ohman, EM; Oto, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; White, HD; Widimsky, P; Winters, KJ; Wiviott, SD, 2013) |
| "Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed." | 5.16 | Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ, 2012) |
| "Patients with medically managed unstable angina or non-ST-segment elevation myocardial infarction were enrolled in the TRILOGY ACS trial (2008 to 2011) comparing clopidogrel vs prasugrel." | 5.16 | Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. ( Armstrong, PW; Brown, E; Chan, MY; Cornel, JH; Erlinge, D; Fox, KA; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Neely, B; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD; Zhou, C, 2012) |
| "We studied 13 608 patients with acute coronary syndrome undergoing percutaneous coronary intervention randomized to prasugrel or clopidogrel and treated for 6 to 15 months in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI 38)." | 5.14 | Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi ( Antman, EM; Bonaca, MP; Bramucci, E; Braunwald, E; McCabe, CH; Morrow, DA; Murphy, SA; Nicolau, JC; Ruff, CT; Scirica, BM; White, HD; Wiviott, SD, 2009) |
| " Among a high-risk NSTEMI population not undergoing PCI within 24 hours of arrival, the nonrandomized short-term use of clopidogrel is associated with a lower risk of inhospital mortality without an increased risk of major bleeding." | 5.13 | Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Su ( Alexander, D; Brown, DL; Cannon, CP; Fintel, DJ; Gibler, WB; Ohman, EM; Ou, FS; Peterson, ED; Pollack, CV; Roe, MT, 2008) |
| "Prasugrel is superior to clopidogrel in preventing ischemic events in patients with an acute coronary syndrome who are undergoing percutaneous coronary intervention, but it is associated with an increased risk of major bleeding." | 5.13 | Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys ( Antman, EM; Braunwald, E; Chandna, H; Hasin, Y; Macias, W; McCabe, CH; Murphy, SA; Voitk, J; Widimsky, P; Wiviott, SD, 2008) |
| " The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial demonstrated the effectiveness of clopidogrel plus acetylsalicylic acid (ASA) compared with ASA alone in reducing cardiovascular events in patients with acute coronary syndromes and, in addition, patients undergoing percutaneous coronary intervention in the Percutaneous Coronary Intervention in CURE (PCI-CURE) trial." | 5.12 | Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial. ( Kolm, P; Mehta, SR; O'Brien, JA; Veledar, E; Weintraub, WS; Yuan, Y, 2007) |
| " The aim of the study was to assess the impact of clopidogrel on safety and efficacy in patients with renal dysfunction in non-ST elevation acute coronary syndromes." | 5.12 | Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. ( Hawken, S; Keltai, M; Lewis, BS; Mann, JF; Mehta, SR; Sitkei, E; Tonelli, M; Yusuf, S, 2007) |
| "Aspirin resistance may increase up to more then threefold the risk of major cardiovascular events (MACE) in patients with stable coronary artery disease." | 5.12 | The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. ( Mercanoglu, F; Meric, M; Nisanci, Y; Oflaz, H; Oncul, A; Ozcan, M; Pamukcu, B; Umman, B, 2006) |
| "Aspirin can inhibit inflammatory reactions and platelet aggregation, but little is known about the effects of the combination of aspirin plus clopidogrel, a new antiplatelet agent, on inflammation." | 5.12 | Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. ( Chen, YG; Ji, QS; Li, RJ; Lü, RJ; Sun, Y; Xu, F; Zhang, Y, 2006) |
| "In patients with NSTE-ACS undergoing early invasive strategy, the adjunctive administration of upstream tirofiban did not reduce the peak values and the cumulative release of myocardial necrosis markers, compared with aspirin, heparin, and clopidogrel given on admission and associated with selective use of abciximab just before PCI." | 5.11 | Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstrea ( Badia, T; Bellandi, F; Dabizzi, RP; De Servi, S; Leoncini, M; Maioli, M; Politi, A; Toso, A, 2005) |
| "In the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial, 12 562 patients were randomized to clopidogrel or placebo in addition to aspirin, and the primary outcome was cardiovascular (CV) death, myocardial infarction (MI), or stroke." | 5.11 | Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. ( Fox, KA; Gersh, BJ; Lakkis, N; Mehta, SR; Peters, R; Yusuf, S; Zhao, F, 2004) |
| "We studied the benefits and risks of adding clopidogrel to different doses of aspirin in the treatment of patients with acute coronary syndrome (ACS)." | 5.10 | Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. ( Commerford, PJ; Diaz, R; Fox, KA; Kopecky, SL; Lewis, BS; Mehta, SR; Peters, RJ; Valentin, V; Yusuf, S; Zhao, F, 2003) |
| "Data collected to investigate the effects of ticlopidine in a subset of 489 patients with angina at rest accompanied by transient ischaemic electrocardiographic changes have been analysed." | 5.07 | Ticlopidine treatment for patients with unstable angina at rest. A further analysis of the study of ticlopidine in unstable angina. Studio della Ticlopidina nell'Angina Instabile Group. ( Lagioia, R; Rizzon, P; Scrutinio, D, 1991) |
| " The long-term benefit of dual anti-platelet therapy with clopidogrel and aspirin is well established for patients with acute coronary syndrome and for secondary prophylaxis of coronary artery disease." | 4.86 | [Platelet inhibition with prasugrel]. ( Caglayan, E; Er, F; Erdmann, E; Gassanov, N; Nia, AM, 2010) |
| " This article reviews the mechanism of action and the major evidence supporting the clinical use of clopidogrel, a potent antiplatelet agent of the thienopyridines class, focusing on its role in the setting of acute coronary syndromes without persistent ST segment elevation (unstable angina and non-Q wave myocardial infarction)." | 4.82 | Clopidogrel in acute coronary syndromes (unstable angina and non-Q-wave myocardial infarction). ( Heras, M; Sionis, A, 2003) |
| " The CURE study evaluated the efficacy and safety of clopidogrel on top of acetylsalicylic acid (ASA) versus standard therapy (including ASA) in over 12,000 patients with unstable angina or non-ST-segment elevation myocardial infarction (MI)." | 4.82 | Recent clinical trial results with antiplatelet therapy: implications in stroke prevention. ( Teal, PA, 2004) |
| " Beta-blockers, nitrates, and calcium-channel blockers are useful for antiischemic therapy in patients with acute coronary syndromes." | 4.81 | [Acute coronary syndromes: an update. I. Pathogenesis and drug therapy]. ( Auer, J; Berent, R; Eber, B; Maurer, E; Mayr, H; Weber, T, 2001) |
| " coronary angioplasty (PTCA) with or without stent implantation), and in unstable angina/non-ST-segment elevation myocardial infarction, the risk of acute vessel occlusion by thrombosis is high in spite of treatment with aspirin and heparin." | 4.81 | Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction. ( Bosch, X; Marrugat, J, 2001) |
| " In the CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events) Trial, clopidogrel (clopidogrel bisulphate) was superior to acetylsalicylic acid (ASA) in reducing the combined risk of ischaemic stroke (IS), myocardial infarction (MI) or vascular death in patients with symptomatic atherosclerosis." | 4.81 | From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. ( Hacke, W, 2002) |
| " On the contrary, the initial treatment with clopidogrel in addition to aspirin and anticoagulation led to a 20% relative risk reduction for an endpoint of death, myocardial infarction and stroke in the CURE trial." | 4.81 | [Modern therapy in acute coronary syndrome]. ( Blankenberg, S; Espinola-Klein, C; Meyer, J; Rupprecht, HJ, 2002) |
| "This study sought to examine the effectiveness of clopidogrel in real-world, medically managed patients with unstable angina (UA) or non-ST-segment elevation myocardial infarction (NSTEMI)." | 3.80 | Comparative effectiveness of clopidogrel in medically managed patients with unstable angina and non-ST-segment elevation myocardial infarction. ( Boothroyd, DB; Chang, TI; Go, AS; Hlatky, MA; Kazi, DS; Leong, TK; Shilane, D; Solomon, MD, 2014) |
| "Antithrombotic treatment of unstable angina is a highly controversial subject." | 3.79 | [Antithrombotic agents in unstable angina. Review of clinical trials]. ( Habis, M; Morice, MC, 1998) |
| "One-year treatment with clopidogrel in addition to aspirin is a cost-effective treatment option for secondary prevention in patients with acute coronary syndrome without ST-segment elevation in Greece." | 3.78 | Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis. ( Fragoulakis, V; Kourlaba, G; Maniadakis, N, 2012) |
| "Platelet function analyses, which included measures of platelet aggregation and activation, were performed in 173 T2DM patients with coronary artery disease on chronic treatment with aspirin and clopidogrel." | 3.74 | Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. ( Alfonso, F; Angiolillo, DJ; Bañuelos, C; Bass, TA; Bernardo, E; Costa, MA; Escaned, J; Fernandez-Ortiz, A; Guzman, LA; Hernández-Antolin, R; Jimenez-Quevedo, P; Macaya, C; Moreno, R; Palazuelos, J; Sabaté, M, 2007) |
| "Recent studies have suggested that low-dose aspirin has preserved benefit with less bleeding compared with standard-dose aspirin when given with or without clopidogrel in patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACSs)." | 3.74 | Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative. ( Cannon, CP; Gibler, WB; Milford-Beland, S; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Tickoo, S, 2007) |
| "Clopidogrel added to aspirin improved outcomes after hospitalization in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) in the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial, regardless of in-hospital treatment approach." | 3.73 | Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. ( Bhatt, DL; Cannon, CP; Fintel, DJ; Gibler, WB; Harrington, RA; Mulgund, J; Newby, LK; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Smith, SC; Tricoci, P, 2006) |
| "The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study showed that patients with unstable angina pectoris (UAP) and non-ST-elevation myocardial infarction (NSTEMI) benefit from combined therapy with acetylsalicylic acid (ASA) and clopidogrel." | 3.73 | [Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome]. ( Kjaer, J; Larsen, CH; Mickley, H; Møller, JE; Poulsen, TS, 2006) |
| " 178 consecutive patients admitted for acute coronary syndrome received 250 mg of intravenous aspirin together with either a loading dose of 300 mg of clopidogrel (n = 104) or 600 mg (n = 74) administered 12 to 24 hours prior to coronary angiography." | 3.73 | [Beneficial effect of a loading dose of 600 mg of clopidogrel on platelet parameters in patients admitted for acute coronary syndrome]. ( Alessi, MC; Bonnet, JL; Carvajal, J; Cuisset, T; Frère, C; Lambert, M; Morange, PE; Mouret, JP; Quilici, J; Saidi, LN, 2006) |
| "Clopidogrel given for up to 1 year in patients undergoing PCI after presentation with acute coronary syndromes is a highly cost-effective treatment strategy." | 3.73 | Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. ( Caro, J; Chen, R; Culler, S; Gabriel, S; Jackson, J; Lamy, A; Mahoney, EM; Mehta, S; Weintraub, WS; Yuan, Y; Yusuf, S, 2006) |
| " The cost-effectiveness of longer combination therapy depends critically on the balance of thrombotic event rates, durable efficacy, and the increased bleeding rate in patients taking clopidogrel." | 3.73 | A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. ( Heidenreich, PA; Schleinitz, MD, 2005) |
| "Utilizing data from the Global Registry of Acute Coronary Events, we studied 15 693 patients admitted with non-ST-segment elevation myocardial infarction (MI) or unstable angina, dividing them according to discharge medications: aspirin alone (group I); aspirin + clopidogrel (group II); aspirin + statin (group III); aspirin + clopidogrel + statin (group IV)." | 3.73 | Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. ( Agnelli, G; Dabbous, OH; Dibenedetto, D; Eagle, KA; Gore, JM; Kline-Rogers, EM; Lim, MJ; Mehta, RH; Spencer, FA, 2005) |
| "We sought to characterize patterns of clopidogrel use before coronary artery bypass grafting (CABG) and examine the drug's impact on risks for postoperative transfusions among patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS)." | 3.73 | Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. ( Cannon, CP; Ferguson, TB; Gibler, WB; Mehta, RH; Mulgund, J; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Smith, SC, 2006) |
| "We performed a retrospective analysis of the Mayo Clinic PCI database and identified 66 consecutive patients who were discharged from hospital after PCI between January 2000 and August 2002 (inclusive) receiving a combination of dual antiplatelet therapy (aspirin and clopidogrel) and systemic anticoagulation (warfarin) to determine the incidence of bleeding and other clinical events during the treatment period." | 3.72 | Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. ( Berger, PB; Burger, K; Fasseas, P; Holmes, DR; Melby, S; Orford, JL; Steinhubl, SR, 2004) |
| "The possible additive antiplatelet effects of aspirin and clopidogrel have been explored in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) and Management of Atherothrombosis with Clopidogrel in High Risk Patients (MATCH) studies." | 3.72 | Long-term combination therapy with aspirin and clopidogrel. ( Cheung, BM; Cheung, G; Kumana, CR; Lauder, IJ, 2004) |
| "We report a case of a 76-year-old-man who developed spontaneous hemarthrosis of his right knee following clopidogrel-aspirin treatment." | 3.72 | Spontaneous hemarthrosis of the knee associated with clopidogrel and aspirin treatment. ( Behrens, P; Bernotat, J; Böhm, S; Gille, J; Löhr, JF, 2003) |
| "In the ASCET study, 1000 patients with documented coronary heart disease will be randomized to either continued treatment with aspirin 160 mg/d or change to clopidogrel 75 mg/d after initial determination of their platelet reactivity while on aspirin treatment." | 3.72 | Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. ( Abdelnoor, M; Arnesen, H; Pettersen, AA; Seljeflot, I, 2004) |
| " The main findings are related to the developing role of Chest Pain Units in the management and early risk stratification of acute coronary syndromes in the emergency department; new information concerning the efficacy of glycoprotein IIb/IIIa inhibitors, clopidogrel and low-molecular-weight heparins in the pharmacological treatment of acute coronary syndromes without ST-segment elevation; and the role of early invasive strategy in improving the prognosis of these patients." | 3.71 | [2002 Update of the Guidelines of the Spanish Society of Cardiology for Unstable Angina/Without ST-Segment Elevation Myocardial Infarction]. ( Alonso, JJ; Arós Borau, F; Bayón Fernández, J; Bueno, H; Cequier Fillat, A; Coma Canella, I; Fernández-Ortiz, A; Lidón Corbi, RM; Loma-Osorio, A; López Bescós, L; Marrugat De La Iglesia, J; Masiá Martorell, R; Palencia Pérez, M; Tuñón Fernández, J, 2002) |
| " The CURE trial shows that clopidogrel in addition to aspirin achieves this double goal, with a 20% relative risk reduction in the primary composite endpoint of cardiovascular death, myocardial infarction or stroke in the first 30 days." | 3.71 | [Clopidogrel in acute coronary syndromes with non-ST elevation. Clinical implications of the CURE trial]. ( Valentín, V, 2001) |
| "ASPIRIN AND HEPARIN: In several studies aspirin has been found to be very effective in unstable angina pectoris reducing fatal and non-fatal myocardial infarction by 50-70%." | 3.71 | [Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions]. ( Huber, K; Niessner, A; Niessner, H, 2001) |
| "Aspirin is an established therapy for the management of acute myocardial infarction (AMI) and unstable angina." | 3.70 | New antiplatelet agents. ( Ellis, CJ; French, JK; White, HD, 1998) |
| " We analyzed the early (30 days) and late outcome of a cohort of 459 consecutive patients who underwent stent placement with ticlopidine and aspirin as antithrombotic regimen according to the presence (group 1, n = 151) or absence (group 2, n = 308) of unstable angina at rest (Braunwald classes II and III)." | 3.70 | Long-term outcome in patients treated by intracoronary stenting with ticlopidine and aspirin, and deleterious prognostic role of unstable angina pectoris. ( Alla, F; Angioi, M; Cherrier, F; Danchin, N; Gangloff, C; Grentzinger, A; Houplon, P; Juillière, Y; Preiss, JP; Rodriguez, RM; Sunthorn, H, 2000) |
| "(1) Aspirin reduces acute-phase mortality after myocardial infarction, and also reduces the risk of myocardial infarction and death in patients with unstable angina." | 3.70 | Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention. ( , 2000) |
| "Patients with unstable angina pectoris undergoing percutaneous coronary intervention (PCI) received either a daily dose of clopidogrel 75mg (n=23) or prasugrel 10mg (n=22)." | 2.84 | Prasugrel as opposed to clopidogrel improves endothelial nitric oxide bioavailability and reduces platelet-leukocyte interaction in patients with unstable angina pectoris: A randomized controlled trial. ( Baldus, S; Friedrichs, K; Fuchs, A; Hellmich, M; Klinke, A; Mollenhauer, M; Rudolph, TK; Rudolph, V; Schlichting, A; Schwedhelm, E, 2017) |
| "0001), and major adverse cardiac events (8." | 2.73 | Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy). ( Holmes, DR; Kuntz, RE; Leon, MB; Mishkel, G; Moses, JW; Popma, JJ; Raizner, AE; Satler, LF; Teirstein, PS; Wang, P; Weisz, G; Wilensky, RL, 2007) |
| "When ticlopidine was given for 72 hours, TF levels were similar to normal laboratory values both in stable and unstable patients." | 2.69 | Effect of aspirin and ticlopidine on plasma tissue factor levels in stable and unstable angina pectoris. ( Ariëns, RA; Bernies, M; Bossi, IM; Brambilla, GM; Donatelli, F; Fajadet, J; Gregorini, L; Marco, I; Marco, J; Mari, D; Romano, SM; Somalvico, F, 2000) |
| "Ticlopidine was found to produce more marked effects on ADT-induced plasma platelet aggregation, in vivo reversible platelet aggregation, and reduced platelet levels of free cholesterol, as compared to aspirin." | 2.67 | [Ticlopidine and aspirin in the treatment of unstable angina: comparative evaluation of their effect of anti-aggregation and platelet membranes]. ( Mezhetskaia, IA; Shalaev, SV, 1993) |
| "Patients with unstable angina pectoris/non-ST-elevation myocardial infarction (NSTEMI) should be treated with dual antiplatelet therapy with the use of aspirin plus either clopidogrel, prasugrel, or ticagrelor depending on the clinical circumstances as discussed in this article." | 2.49 | Use of antiplatelet drugs in the treatment of acute coronary syndromes. ( Aronow, WS, 2013) |
| "Non-ST elevation acute coronary syndromes are responsible for approximately 1 million admissions to U." | 2.48 | Unstable angina and non-ST elevation myocardial infarction. ( Braunwald, E, 2012) |
| "Despite many recent advancements in the treatment of coronary heart disease, it continues to be an important source of patient morbidity and mortality as well as a significant source of healthcare-related expenditures." | 2.44 | The role of clopidogrel in revascularized and nonrevascularized patients with acute coronary syndromes. ( Collins, JS; Gurm, HS, 2007) |
| "As well as initiating thrombus formation at the site of a ruptured atherosclerotic plaque, platelets play a key role in vascular inflammation, through release of their own pro-inflammatory mediators and interactions with other relevant cell types (endothelial cells, leukocytes, and smooth muscle cells)." | 2.44 | Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. ( Badimon, JJ; Bhatt, DL; Herbert, JM; Lüscher, TF; Steinhubl, SR, 2007) |
| "We report a case of multiple coronary thrombosis involving the left anterior descending artery and circumflex artery and stent implantation to the subtotally stenotic right renal artery in a women with unstable angina pectoris, essential thrombocytosis and previous history of renal artery trombosis." | 2.43 | Multiple coronary thrombosis and stent implantation to the subtotally occluded right renal artery in a patient with essential thrombocytosis: a case report with review. ( Bugra, Z; Ekmekci, A; Meric, M; Ozben, B; Umman, S, 2006) |
| "Elderly patients with unstable angina pectoris/non-ST-segment elevation myocardial infarction should be hospitalized." | 2.42 | Treatment of unstable angina pectoris/non-ST-segment elevation myocardial infarction in elderly patients. ( Aronow, WS, 2003) |
| "Aspirin, however, has become a lifelong therapy for many patients, based on clinical trials and medical experience." | 2.42 | Role of clopidogrel in unstable angina and non-ST-segment elevation myocardial infarction: from literature and guidelines to practice. ( Kerr, JL; Oppelt, TF; Rowen, RC, 2004) |
| " Regarding the postoperative course, significant results could be demonstrated for: adrenaline dosage (0." | 1.36 | Mid-term outcomes of patients with PCI prior to CABG in comparison to patients with primary CABG. ( Adamczak, M; Boulesteix, AL; Eifert, S; Kilian, E; Lamm, P; Mair, H; Reichart, B, 2010) |
| "Serious allergic reactions have also been reported; (6) In most cases, especially when the risk of restenosis is low or moderate, it is better to use a bare metal stent." | 1.35 | Drug-eluting coronary stents: many meta-analyses, little benefit. ( , 2009) |
| "Fondaparinux was found to be noninferior to enoxaparin and was associated with fewer bleeding events in the OASIS-5 study of patients who were not treated with an early invasive approach." | 1.35 | 2007 Guideline update for unstable angina/non-ST-segment elevation myocardial infarction: focus on antiplatelet and anticoagulant therapies. ( Battistone, S; Coons, JC, 2008) |
| "Although obesity is a known risk factor for coronary artery disease, its impact on the presentation, treatment, and outcome of patients with acute coronary syndromes (ACS) has not been well studied." | 1.33 | The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart A ( Boden, WE; Diercks, DB; Gibler, WB; Kirk, JD; Mulgund, J; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Smith, SC, 2006) |
| "Ticlopidine has been reported to have major hematologic adverse effects, including neutropenia and thrombotic thrombocytopenic purpura or hemolytic uremic syndrome (HUS)." | 1.31 | Hemolytic uremic syndrome associated with clopidogrel: a case report. ( Marcoux, JP; Moy, B; Raffel, GD; Wang, JC, 2000) |
| " We present several illustrative cases in which platelet monitoring with the Rapid Platelet Function Assay (RPFA, Accumetrics) was used to guide dosing of a glycoprotein (GP) IIb/IIIa inhibitor for coronary and peripheral intervention among patients at increased bleeding risk." | 1.31 | Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. ( Chew, DP; Moliterno, DJ; Mukherjee, D; Raymond, RE; Robbins, M; Yadav, JS, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.41) | 18.7374 |
| 1990's | 20 (8.23) | 18.2507 |
| 2000's | 177 (72.84) | 29.6817 |
| 2010's | 45 (18.52) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rudolph, TK | 1 |
| Fuchs, A | 1 |
| Klinke, A | 1 |
| Schlichting, A | 1 |
| Friedrichs, K | 1 |
| Hellmich, M | 1 |
| Mollenhauer, M | 1 |
| Schwedhelm, E | 1 |
| Baldus, S | 1 |
| Rudolph, V | 1 |
| Stathopoulou, MG | 1 |
| Monteiro, P | 1 |
| Shahabi, P | 1 |
| Peñas-Lledó, E | 1 |
| El Shamieh, S | 1 |
| Silva Santos, L | 1 |
| Thilly, N | 1 |
| Siest, G | 1 |
| Llerena, A | 1 |
| Visvikis-Siest, S | 1 |
| Cano, P | 1 |
| Consuegra-Sánchez, L | 1 |
| Conesa, P | 1 |
| Torres-Moreno, D | 1 |
| Jaulent, L | 1 |
| Dau, D | 1 |
| Picó, F | 1 |
| Villegas, M | 1 |
| Aronow, WS | 2 |
| Swaminathan, RV | 1 |
| Feldman, DN | 1 |
| Wiviott, SD | 3 |
| White, HD | 9 |
| Ohman, EM | 17 |
| Fox, KA | 14 |
| Armstrong, PW | 8 |
| Prabhakaran, D | 7 |
| Hafley, G | 2 |
| Lokhnygina, Y | 4 |
| Boden, WE | 5 |
| Hamm, C | 2 |
| Clemmensen, P | 3 |
| Nicolau, JC | 3 |
| Menozzi, A | 1 |
| Ruzyllo, W | 2 |
| Widimsky, P | 3 |
| Oto, A | 2 |
| Leiva-Pons, J | 1 |
| Pavlides, G | 2 |
| Winters, KJ | 3 |
| Roe, MT | 17 |
| Bhatt, DL | 8 |
| Li, X | 1 |
| Zhang, L | 2 |
| Chen, X | 1 |
| Qu, F | 1 |
| Li, J | 2 |
| Ma, C | 1 |
| Yang, J | 1 |
| Xu, B | 1 |
| Wang, H | 1 |
| Xu, Q | 1 |
| Zhang, Y | 2 |
| Li, Y | 1 |
| Lu, C | 1 |
| Yin, T | 1 |
| Meinertz, T | 1 |
| Schäfer, A | 1 |
| Arntz, HR | 1 |
| Boudriot, E | 1 |
| Garlichs, C | 1 |
| Hoffmann, S | 1 |
| Ince, H | 1 |
| Klingenheben, T | 1 |
| Weil, J | 1 |
| Zugck, C | 1 |
| Helms, TM | 1 |
| Silber, S | 1 |
| Zaval's'ka, TV | 1 |
| Harskamp, RE | 1 |
| Solomon, MD | 1 |
| Go, AS | 1 |
| Shilane, D | 1 |
| Boothroyd, DB | 1 |
| Leong, TK | 1 |
| Kazi, DS | 1 |
| Chang, TI | 1 |
| Hlatky, MA | 1 |
| De Servi, S | 2 |
| Goedicke, J | 1 |
| Schirmer, A | 1 |
| Bakal, JA | 1 |
| Goodman, SG | 3 |
| Zheng, Y | 1 |
| Westerhout, CM | 1 |
| Hochman, JS | 4 |
| Brown, EB | 2 |
| Ciolino, JD | 1 |
| Carter, RE | 1 |
| Lüscher, TF | 2 |
| Cyr, DD | 1 |
| Neely, ML | 2 |
| McGuire, DK | 2 |
| Cornel, JH | 4 |
| Huber, K | 6 |
| Zamoryakhin, D | 1 |
| Zhang, N | 1 |
| Chen, KY | 1 |
| Zhao, J | 1 |
| Xu, G | 1 |
| Li, G | 1 |
| Liu, T | 1 |
| Hagström, E | 1 |
| Sidhu, MS | 1 |
| Neely, B | 2 |
| Jakubowski, JA | 2 |
| Ardissino, D | 2 |
| Erlinge, D | 2 |
| Tantry, US | 2 |
| Gurbel, PA | 3 |
| Coons, JC | 1 |
| Battistone, S | 1 |
| Kastrati, A | 3 |
| Neumann, FJ | 2 |
| Mehilli, J | 3 |
| Byrne, RA | 1 |
| Iijima, R | 1 |
| Büttner, HJ | 1 |
| Khattab, AA | 1 |
| Schulz, S | 1 |
| Blankenship, JC | 1 |
| Pache, J | 1 |
| Minners, J | 1 |
| Seyfarth, M | 1 |
| Graf, I | 1 |
| Skelding, KA | 1 |
| Dirschinger, J | 3 |
| Richardt, G | 1 |
| Berger, PB | 5 |
| Schömig, A | 3 |
| Alexander, D | 1 |
| Ou, FS | 2 |
| Pollack, CV | 7 |
| Cannon, CP | 5 |
| Gibler, WB | 7 |
| Fintel, DJ | 2 |
| Peterson, ED | 8 |
| Brown, DL | 1 |
| Nurözler, F | 1 |
| Kutlu, T | 1 |
| Küçük, G | 1 |
| Wang, TY | 1 |
| Harrington, RA | 3 |
| Guerra, M | 1 |
| Mota, JC | 1 |
| Veloso, M | 1 |
| Gama, V | 1 |
| Vouga, L | 1 |
| Morrow, DA | 1 |
| Bramucci, E | 1 |
| Murphy, SA | 2 |
| Bonaca, MP | 1 |
| Ruff, CT | 1 |
| Scirica, BM | 1 |
| McCabe, CH | 2 |
| Antman, EM | 3 |
| Braunwald, E | 5 |
| Davlouros, PA | 1 |
| Arseniou, A | 1 |
| Hahalis, G | 1 |
| Chiladakis, J | 1 |
| Mazarakis, A | 1 |
| Damelou, A | 1 |
| Karakantza, M | 1 |
| Paliogianni, F | 1 |
| Karogiannis, N | 1 |
| Alexopoulos, D | 1 |
| Ishikawa, T | 1 |
| Nakano, Y | 1 |
| Endoh, A | 1 |
| Kubota, T | 1 |
| Suzuki, T | 1 |
| Nakata, K | 1 |
| Miyamoto, T | 1 |
| Murakami, M | 1 |
| Sakamoto, H | 1 |
| Imai, K | 1 |
| Mochizuki, S | 1 |
| Yoshimura, M | 1 |
| Mutoh, M | 1 |
| Damman, P | 1 |
| Hirsch, A | 1 |
| Windhausen, F | 1 |
| Tijssen, JG | 1 |
| de Winter, RJ | 1 |
| Zafar, MU | 1 |
| Paz-Yepes, M | 1 |
| Shimbo, D | 1 |
| Vilahur, G | 1 |
| Burg, MM | 1 |
| Chaplin, W | 1 |
| Fuster, V | 2 |
| Davidson, KW | 1 |
| Badimon, JJ | 2 |
| Kloppenburg, G | 1 |
| Zairis, MN | 1 |
| Tsiaousis, GZ | 1 |
| Patsourakos, NG | 1 |
| Georgilas, AT | 1 |
| Kontos, CF | 1 |
| Adamopoulou, EN | 1 |
| Vogiatzidis, K | 1 |
| Argyrakis, SK | 1 |
| Fakiolas, CN | 1 |
| Foussas, SG | 1 |
| Sorich, MJ | 1 |
| Vitry, A | 1 |
| Ward, MB | 1 |
| Horowitz, JD | 1 |
| McKinnon, RA | 1 |
| Chin, CT | 1 |
| Marshall, DA | 1 |
| Petitjean, H | 1 |
| Brown, E | 2 |
| Bonassin, F | 1 |
| Wyss, C | 1 |
| Schneemann, M | 1 |
| Gassanov, N | 1 |
| Caglayan, E | 1 |
| Nia, AM | 1 |
| Erdmann, E | 2 |
| Er, F | 1 |
| Zeymer, U | 1 |
| Zahn, R | 1 |
| Senges, J | 1 |
| Gitt, A | 1 |
| Eifert, S | 1 |
| Mair, H | 1 |
| Boulesteix, AL | 1 |
| Kilian, E | 1 |
| Adamczak, M | 1 |
| Reichart, B | 1 |
| Lamm, P | 1 |
| Blackburn, DF | 1 |
| Lamb, DA | 1 |
| Mcleod, MM | 1 |
| Eurich, DT | 1 |
| Merella, P | 1 |
| Casu, G | 1 |
| Meloni, I | 1 |
| Vogel, B | 1 |
| Hahne, S | 1 |
| Kozanli, I | 1 |
| Kalla, K | 1 |
| Jarai, R | 1 |
| Freynhofer, M | 1 |
| Smetana, P | 1 |
| Nürnberg, M | 1 |
| Geppert, A | 1 |
| Unger, G | 1 |
| Paré, G | 1 |
| Ross, S | 1 |
| Mehta, SR | 10 |
| Yusuf, S | 10 |
| Anand, SS | 1 |
| Connolly, SJ | 1 |
| Eikelboom, JW | 1 |
| Vassilev, D | 1 |
| Hazan, M | 1 |
| Dean, L | 1 |
| Jia, XQ | 1 |
| Dong, CM | 1 |
| Qin, J | 1 |
| Lewis, JP | 1 |
| Shuldiner, AR | 1 |
| Kourlaba, G | 1 |
| Fragoulakis, V | 1 |
| Maniadakis, N | 1 |
| Tu, YH | 1 |
| Hsu, JC | 1 |
| Martinez, F | 1 |
| Dalby, AJ | 1 |
| Leiva-Pons, JL | 1 |
| Parkhomenko, A | 1 |
| Gottlieb, S | 1 |
| Topacio, GO | 1 |
| Goudev, AR | 1 |
| Tseng, CD | 1 |
| Merkely, B | 1 |
| Gasparovic, V | 1 |
| Corbalan, R | 1 |
| Cinteză, M | 1 |
| McLendon, RC | 1 |
| Aylward, PE | 1 |
| Neely, M | 1 |
| Chan, MY | 1 |
| Zhou, C | 1 |
| Lynch, DR | 1 |
| Dantzler, DM | 1 |
| Zhao, D | 1 |
| López Bescós, L | 1 |
| Arós Borau, F | 1 |
| Lidón Corbi, RM | 1 |
| Cequier Fillat, A | 1 |
| Bueno, H | 1 |
| Alonso, JJ | 1 |
| Coma Canella, I | 1 |
| Loma-Osorio, A | 1 |
| Bayón Fernández, J | 1 |
| Masiá Martorell, R | 1 |
| Tuñón Fernández, J | 1 |
| Fernández-Ortiz, A | 2 |
| Marrugat De La Iglesia, J | 1 |
| Palencia Pérez, M | 1 |
| Natarajan, M | 5 |
| Beasley, JW | 1 |
| Califf, RM | 2 |
| Cheitlin, MD | 1 |
| Jones, RH | 1 |
| Kereiakes, D | 1 |
| Kupersmith, J | 1 |
| Levin, TN | 1 |
| Pepine, CJ | 2 |
| Schaeffer, JW | 1 |
| Smith, EE | 1 |
| Steward, DE | 1 |
| Theroux, P | 1 |
| Gibbons, RJ | 1 |
| Alpert, JS | 1 |
| Faxon, DP | 1 |
| Gregoratos, G | 1 |
| Hiratzka, LF | 1 |
| Jacobs, AK | 1 |
| Smith, SC | 5 |
| Steinhubl, S | 1 |
| Alberts, MJ | 1 |
| Easton, JD | 1 |
| McRedmond, J | 1 |
| Fitzgerald, D | 1 |
| Valentín Segura, V | 1 |
| Orford, JL | 2 |
| Lennon, R | 1 |
| Melby, S | 2 |
| Fasseas, P | 2 |
| Bell, MR | 1 |
| Rihal, CS | 1 |
| Holmes, DR | 3 |
| Howard, PA | 1 |
| Zaliūnas, R | 1 |
| Bahrmann, P | 1 |
| Sigusch, HH | 1 |
| Surber, R | 1 |
| Figulla, HR | 1 |
| Hughes, K | 1 |
| Zhao, F | 5 |
| Gersh, BJ | 2 |
| Commerford, PJ | 2 |
| Blumenthal, M | 1 |
| Budaj, A | 2 |
| Wittlinger, T | 1 |
| Gille, J | 1 |
| Bernotat, J | 1 |
| Böhm, S | 1 |
| Behrens, P | 1 |
| Löhr, JF | 1 |
| Joyner, CD | 1 |
| Flather, M | 1 |
| Gerschutz, GP | 1 |
| Soffer, D | 1 |
| Moussa, I | 1 |
| Harjai, KJ | 1 |
| Boura, JA | 1 |
| Dixon, SR | 1 |
| Grines, CL | 1 |
| O'Neill, WW | 1 |
| Roubin, GS | 1 |
| Moses, JW | 2 |
| Heras, M | 1 |
| Sionis, A | 1 |
| Schroeder, WS | 1 |
| Gandhi, PJ | 1 |
| Fries, R | 1 |
| Böhm, M | 1 |
| Blanchard, D | 1 |
| Demicheli, T | 1 |
| Danchin, N | 2 |
| Kopp, CW | 1 |
| Steiner, S | 1 |
| Priglinger, U | 1 |
| Christ, G | 1 |
| Probst, P | 1 |
| Maurer, G | 1 |
| Minar, E | 1 |
| Peters, RJ | 4 |
| Lewis, BS | 3 |
| Kopecky, SL | 1 |
| Diaz, R | 1 |
| Valentin, V | 2 |
| Wodlinger, AM | 1 |
| Pieper, JA | 1 |
| Gaitonde, RS | 1 |
| Sharma, N | 1 |
| Ali-Hasan, S | 1 |
| Miller, JM | 1 |
| Jayachandran, JV | 1 |
| Kalaria, VG | 1 |
| Averkov, OV | 1 |
| Slavina, NN | 1 |
| Gratsianskiĭ, NA | 1 |
| Lange, RA | 1 |
| Hillis, LD | 1 |
| Teal, PA | 1 |
| Burger, K | 1 |
| Steinhubl, SR | 3 |
| Kimura, K | 1 |
| Kosuge, M | 1 |
| Rodgers, JE | 1 |
| Collet, JP | 2 |
| Montalescot, G | 3 |
| Golmard, JL | 1 |
| Tanguy, ML | 2 |
| Ankri, A | 2 |
| Choussat, R | 2 |
| Beygui, F | 2 |
| Drobinski, G | 1 |
| Vignolles, N | 1 |
| Thomas, D | 2 |
| Bennett, SK | 1 |
| Redberg, RF | 1 |
| Banas, JS | 1 |
| Herbert, JM | 2 |
| Savi, P | 1 |
| Gawaz, M | 1 |
| Müller, I | 1 |
| Besta, F | 1 |
| Payot, L | 1 |
| Dumaine, R | 1 |
| Gallois, V | 1 |
| Aghababian, RV | 1 |
| Peters, R | 1 |
| Lakkis, N | 1 |
| Hagymási, K | 1 |
| Schwaab, B | 1 |
| Kerr, JL | 1 |
| Oppelt, TF | 1 |
| Rowen, RC | 1 |
| Rupprecht, HJ | 2 |
| Hirsh, J | 1 |
| Heptinstall, S | 1 |
| Glenn, JR | 1 |
| May, JA | 1 |
| Storey, RF | 1 |
| Wilcox, RG | 1 |
| Melero, JM | 1 |
| Porras, C | 1 |
| Such, M | 1 |
| Olalla, E | 1 |
| Alonso, J | 1 |
| Michelson, AD | 1 |
| Garcia, S | 1 |
| Canoniero, MJ | 1 |
| Chirinos, JA | 1 |
| de Marchena, E | 1 |
| Salerno, T | 1 |
| Ferreira, A | 1 |
| Lamy, A | 2 |
| Jönsson, B | 1 |
| Weintraub, WS | 3 |
| Chrolavicius, S | 1 |
| Bakhai, A | 1 |
| Culler, S | 2 |
| Gafni, A | 1 |
| Lindgren, P | 1 |
| Mahoney, E | 1 |
| Mukherjee, D | 3 |
| Kline-Rogers, E | 1 |
| Fang, J | 1 |
| Munir, K | 1 |
| Eagle, KA | 3 |
| von Mach, MA | 1 |
| Eich, A | 1 |
| Weilemann, LS | 1 |
| Münzel, T | 2 |
| Kumana, CR | 1 |
| Cheung, G | 1 |
| Lauder, IJ | 1 |
| Cheung, BM | 1 |
| Schleinitz, MD | 1 |
| Heidenreich, PA | 1 |
| Lim, MJ | 1 |
| Spencer, FA | 1 |
| Gore, JM | 1 |
| Dabbous, OH | 1 |
| Agnelli, G | 1 |
| Kline-Rogers, EM | 1 |
| Dibenedetto, D | 1 |
| Mehta, RH | 3 |
| Schmitt, C | 1 |
| Dibra, A | 2 |
| Volmer, C | 1 |
| Schühlen, H | 2 |
| Dotzer, F | 1 |
| ten Berg, JM | 1 |
| Pettersen, AA | 1 |
| Seljeflot, I | 1 |
| Abdelnoor, M | 1 |
| Arnesen, H | 1 |
| Aranki, S | 1 |
| Byrne, J | 1 |
| Bhatia, D | 1 |
| Mehta, S | 2 |
| Mills, R | 1 |
| Elsässer, A | 1 |
| Nef, H | 1 |
| Möllmann, H | 1 |
| Hamm, CW | 1 |
| Akowuah, E | 1 |
| Shrivastava, V | 1 |
| Jamnadas, B | 1 |
| Hopkinson, D | 1 |
| Sarkar, P | 1 |
| Storey, R | 1 |
| Braidley, P | 1 |
| Cooper, G | 1 |
| Sick, PB | 1 |
| Brosteanu, O | 1 |
| Ulrich, M | 1 |
| Thiele, H | 1 |
| Niebauer, J | 1 |
| Busch, I | 1 |
| Schuler, G | 1 |
| McCollam, P | 1 |
| Etemad, L | 1 |
| Braun, S | 1 |
| Hadamitzky, M | 1 |
| Baum, H | 1 |
| Michowitz, Y | 1 |
| Blatt, A | 1 |
| Frimmerman, A | 1 |
| Finkelstein, A | 1 |
| Massachi, R | 1 |
| Herz, I | 1 |
| Krakover, R | 1 |
| Miller, H | 1 |
| Keren, G | 1 |
| George, J | 1 |
| van der Linden, J | 1 |
| Lindvall, G | 1 |
| Sartipy, U | 1 |
| Leoncini, M | 1 |
| Toso, A | 1 |
| Maioli, M | 1 |
| Bellandi, F | 1 |
| Badia, T | 1 |
| Politi, A | 1 |
| Dabizzi, RP | 1 |
| Eriksson, P | 1 |
| Rothberg, M | 1 |
| Yip, HK | 2 |
| Wu, CJ | 2 |
| Hang, CL | 1 |
| Chang, HW | 1 |
| Hung, WC | 2 |
| Yeh, KH | 2 |
| Yang, CH | 2 |
| Di Nisio, M | 1 |
| Bijsterveld, NR | 1 |
| Meijers, JC | 1 |
| Levi, M | 1 |
| Büller, HR | 1 |
| Halon, DA | 1 |
| Keltai, M | 2 |
| Mahoney, EM | 1 |
| Yuan, Y | 2 |
| Jackson, J | 1 |
| Chen, R | 1 |
| Gabriel, S | 1 |
| Caro, J | 1 |
| Biondi-Zoccai, GG | 1 |
| Abbate, A | 1 |
| Agostoni, P | 1 |
| Valgimigli, M | 1 |
| Sangiorgi, GM | 1 |
| Garcia-Pavia, P | 1 |
| Aguiar-Souto, P | 1 |
| Silva-Melchor, L | 1 |
| Newby, DE | 1 |
| Gidwani, S | 1 |
| Body, R | 1 |
| Chang, LT | 1 |
| Sun, CK | 1 |
| Cheng, CI | 1 |
| Chua, S | 1 |
| Fu, M | 1 |
| Chen, YG | 1 |
| Xu, F | 1 |
| Ji, QS | 1 |
| Sun, Y | 1 |
| Lü, RJ | 1 |
| Li, RJ | 1 |
| Bierbach, B | 1 |
| Horstick, G | 1 |
| Berg, O | 1 |
| Heimann, A | 1 |
| Vahl, CF | 1 |
| Kempski, O | 1 |
| Darius, H | 1 |
| Asaro, PV | 1 |
| Sheldahl, AL | 1 |
| Char, DM | 1 |
| Casella, G | 1 |
| Greco, C | 1 |
| Maggioni, AP | 1 |
| Di Pasquale, G | 1 |
| Tricoci, P | 1 |
| Mulgund, J | 3 |
| Newby, LK | 1 |
| Ikeda, U | 1 |
| Ozben, B | 1 |
| Ekmekci, A | 1 |
| Bugra, Z | 1 |
| Umman, S | 1 |
| Meric, M | 2 |
| Diercks, DB | 1 |
| Kirk, JD | 1 |
| Ferguson, TB | 1 |
| Giugliano, RP | 1 |
| Vavuranakis, M | 1 |
| Latsios, G | 1 |
| Aggelis, D | 1 |
| Bosinakou, I | 1 |
| Karambelas, I | 1 |
| Tousoulis, D | 1 |
| Toutouzas, K | 1 |
| Stefanadis, C | 1 |
| Mannini, L | 1 |
| Marcucci, R | 1 |
| Paniccia, R | 1 |
| Antonucci, E | 1 |
| Giglioli, C | 1 |
| Valente, S | 1 |
| Gori, AM | 1 |
| Prisco, D | 1 |
| Gensini, GF | 1 |
| Abbate, R | 1 |
| Inoue, T | 1 |
| Hikichi, Y | 1 |
| Morooka, T | 1 |
| Yoshida, K | 1 |
| Fujimatsu, D | 1 |
| Komoda, H | 1 |
| Kameda, M | 1 |
| Nonaka, M | 1 |
| Sohma, R | 1 |
| Hashimoto, S | 1 |
| Node, K | 1 |
| Pamukcu, B | 1 |
| Oflaz, H | 1 |
| Oncul, A | 1 |
| Umman, B | 1 |
| Mercanoglu, F | 1 |
| Ozcan, M | 1 |
| Nisanci, Y | 1 |
| Kjaer, J | 1 |
| Larsen, CH | 1 |
| Poulsen, TS | 1 |
| Møller, JE | 1 |
| Mickley, H | 1 |
| Chen, AY | 1 |
| Lytle, BL | 1 |
| Brindis, RG | 1 |
| Fintel, D | 2 |
| Fraulo, ES | 1 |
| Cuisset, T | 1 |
| Frère, C | 1 |
| Quilici, J | 1 |
| Morange, PE | 1 |
| Saidi, LN | 1 |
| Carvajal, J | 1 |
| Lambert, M | 1 |
| Mouret, JP | 1 |
| Alessi, MC | 1 |
| Bonnet, JL | 1 |
| Ziegelstein, RC | 1 |
| Köster, R | 1 |
| Cattaneo, M | 1 |
| Wercules, O | 1 |
| Meireles, GC | 1 |
| Longhi, A | 1 |
| Beltrão, P | 1 |
| Pimenta, J | 1 |
| Aleil, B | 1 |
| Rochoux, G | 1 |
| Monassier, JP | 1 |
| Cazenave, JP | 1 |
| Gachet, C | 1 |
| Weisz, G | 1 |
| Teirstein, PS | 1 |
| Raizner, AE | 1 |
| Satler, LF | 1 |
| Mishkel, G | 1 |
| Wilensky, RL | 1 |
| Wang, P | 1 |
| Kuntz, RE | 1 |
| Popma, JJ | 1 |
| Leon, MB | 1 |
| Liu, QZ | 1 |
| Hong, T | 1 |
| Liu, ZP | 1 |
| Shi, LB | 1 |
| Sheng, QH | 1 |
| Gong, YJ | 1 |
| Meng, L | 1 |
| Jiang, J | 1 |
| Huo, Y | 1 |
| Tonelli, M | 1 |
| Mann, JF | 1 |
| Sitkei, E | 1 |
| Hawken, S | 1 |
| Tickoo, S | 1 |
| Milford-Beland, S | 1 |
| Collins, JS | 1 |
| Gurm, HS | 2 |
| Mardikar, HM | 1 |
| Hiremath, MS | 1 |
| Moliterno, DJ | 2 |
| Mathew, R | 1 |
| Arora, R | 1 |
| Deo, D | 1 |
| Hiremath, JS | 1 |
| Deshpande, NV | 1 |
| Khan, A | 1 |
| Joseph, J | 1 |
| Heeg, BM | 1 |
| Botteman, M | 1 |
| van Hout, BA | 1 |
| Ferguson, JJ | 1 |
| Wilson, JM | 1 |
| Diez, J | 1 |
| Richard Conti, C | 1 |
| Angiolillo, DJ | 1 |
| Bernardo, E | 1 |
| Sabaté, M | 1 |
| Jimenez-Quevedo, P | 1 |
| Costa, MA | 1 |
| Palazuelos, J | 1 |
| Hernández-Antolin, R | 1 |
| Moreno, R | 1 |
| Escaned, J | 1 |
| Alfonso, F | 1 |
| Bañuelos, C | 1 |
| Guzman, LA | 1 |
| Bass, TA | 1 |
| Macaya, C | 2 |
| Simon, DI | 1 |
| Schmaier, AH | 1 |
| Motivala, AA | 1 |
| Tamhane, U | 1 |
| Saab, F | 1 |
| Rogers, EK | 1 |
| Froehlich, J | 1 |
| Moscucci, M | 1 |
| Kolm, P | 1 |
| Veledar, E | 1 |
| O'Brien, JA | 1 |
| Iwahashi, H | 1 |
| Tashiro, T | 1 |
| Morishige, N | 1 |
| Hayashida, Y | 1 |
| Ito, N | 1 |
| Takeuchi, K | 1 |
| Teshima, H | 1 |
| Kuwahara, G | 1 |
| Walker, CW | 1 |
| Dawley, CA | 1 |
| Fletcher, SF | 1 |
| Bruschi, G | 1 |
| Colombo, P | 1 |
| Piccalò, G | 1 |
| Trunfio, S | 1 |
| Colombo, T | 1 |
| Vitali, E | 1 |
| Kirichenko, AA | 1 |
| Mantserova, OA | 1 |
| Lebedeva, AIu | 1 |
| D'iachkova, NV | 1 |
| Voloshina, NM | 1 |
| Mazurov, VI | 1 |
| Nifontov, VM | 1 |
| Tyrenko, VV | 1 |
| Kolina, IG | 1 |
| Cherkashina, AL | 1 |
| Shkodina, NV | 1 |
| Mazalov, KV | 1 |
| Spiropulos, NA | 1 |
| Eremenko, IA | 1 |
| Kuzin, AI | 1 |
| FitzGerald, GA | 2 |
| Nielsen, AA | 1 |
| Veien, KT | 1 |
| Jørgensen, LG | 1 |
| Buck, TC | 1 |
| Brandslund, I | 1 |
| Christensen, C | 1 |
| Voitk, J | 1 |
| Hasin, Y | 1 |
| Chandna, H | 1 |
| Macias, W | 1 |
| Kawai, C | 1 |
| Chaix, AF | 1 |
| Barragan, P | 1 |
| Silvestri, M | 1 |
| Comet, B | 1 |
| Bouvier, JL | 1 |
| Chaix, L | 1 |
| Latour, F | 1 |
| Camilleri, JF | 1 |
| Garcia, P | 1 |
| Shalaev, SV | 1 |
| Mezhetskaia, IA | 1 |
| Verheugt, FW | 1 |
| Patrono, C | 1 |
| Renda, G | 1 |
| Serruys, PW | 1 |
| van Hout, B | 1 |
| Bonnier, H | 1 |
| Legrand, V | 1 |
| Garcia, E | 1 |
| Sousa, E | 1 |
| van der Giessen, W | 1 |
| Colombo, A | 1 |
| Seabra-Gomes, R | 1 |
| Kiemeneij, F | 1 |
| Ruygrok, P | 1 |
| Ormiston, J | 1 |
| Emanuelsson, H | 1 |
| Fajadet, J | 2 |
| Haude, M | 1 |
| Klugmann, S | 1 |
| Morel, MA | 1 |
| Habis, M | 1 |
| Morice, MC | 1 |
| French, JK | 1 |
| Ellis, CJ | 1 |
| Madan, M | 1 |
| Marquis, JF | 1 |
| de May, MR | 1 |
| Laramee, LA | 1 |
| Leddy, D | 1 |
| O'Brien, E | 1 |
| Williams, WL | 1 |
| Higginson, LA | 1 |
| Jelley, J | 1 |
| Reid, F | 1 |
| Johansen, H | 1 |
| Labinaz, M | 1 |
| Bokarev, IN | 1 |
| Aksenova, MB | 1 |
| Khlevchuk, TV | 1 |
| Dovgolis, SA | 1 |
| Cohen, M | 2 |
| Tung, C | 1 |
| Sauri, D | 1 |
| Gheorghiade, M | 1 |
| Burkhard-Meier, C | 1 |
| Deutsch, HJ | 1 |
| Quinn, MJ | 1 |
| Fitzgerald, DJ | 1 |
| Yamaguchi, T | 1 |
| Nakamura, M | 1 |
| Mitsuo, K | 1 |
| Matsuda, K | 1 |
| Weitz, JI | 1 |
| Bates, SM | 1 |
| Angioi, M | 1 |
| Alla, F | 1 |
| Gangloff, C | 1 |
| Sunthorn, H | 1 |
| Rodriguez, RM | 1 |
| Preiss, JP | 1 |
| Grentzinger, A | 1 |
| Houplon, P | 1 |
| Juillière, Y | 1 |
| Cherrier, F | 1 |
| Moy, B | 1 |
| Wang, JC | 1 |
| Raffel, GD | 1 |
| Marcoux, JP | 1 |
| Srivathsan, K | 1 |
| Showalter, JC | 1 |
| Dieter, RS | 1 |
| Rebrov, AP | 3 |
| Voskoboĭ, IV | 3 |
| Marco, J | 1 |
| Ariëns, RA | 1 |
| Bossi, IM | 1 |
| Marco, I | 1 |
| Bernies, M | 1 |
| Romano, SM | 1 |
| Donatelli, F | 1 |
| Brambilla, GM | 1 |
| Somalvico, F | 1 |
| Mari, D | 1 |
| Gregorini, L | 1 |
| Peter, K | 1 |
| Nordt, T | 1 |
| Bode, C | 1 |
| Topol, EJ | 1 |
| Auer, J | 1 |
| Berent, R | 1 |
| Maurer, E | 1 |
| Mayr, H | 1 |
| Weber, T | 1 |
| Eber, B | 1 |
| Niessner, A | 1 |
| Niessner, H | 1 |
| Chew, DP | 1 |
| Robbins, M | 1 |
| Yadav, JS | 1 |
| Raymond, RE | 1 |
| Kirichuk, VF | 1 |
| Pozin, PIa | 1 |
| Stables, RH | 1 |
| Lassila, R | 1 |
| Bosch, X | 1 |
| Marrugat, J | 1 |
| Denktas, AE | 1 |
| Bayes-Genis, A | 1 |
| Schwartz, RS | 1 |
| Albers, GW | 1 |
| Amarenco, P | 1 |
| Morais, J | 1 |
| Hacke, W | 1 |
| Bahit, MC | 1 |
| Granger, CB | 1 |
| Wallentin, L | 1 |
| Blankenberg, S | 1 |
| Espinola-Klein, C | 1 |
| Meyer, J | 1 |
| Reed, MD | 1 |
| Bell, D | 1 |
| Harding, SA | 1 |
| Boon, NA | 1 |
| Flapan, AD | 1 |
| Khot, UN | 1 |
| Nissen, SE | 1 |
| Scrutinio, D | 2 |
| Lagioia, R | 1 |
| Rizzon, P | 2 |
| Balsano, F | 2 |
| Violi, F | 2 |
| Cimminiello, C | 2 |
| Aguglia, F | 1 |
| Pasotti, C | 1 |
| Rudelli, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prasugrel in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients[NCT04445623] | Phase 3 | 128 participants (Anticipated) | Interventional | 2020-07-31 | Not yet recruiting | ||
| A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed[NCT00699998] | Phase 3 | 9,326 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Prospective, Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Bivalirudin and Un-fractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions. ISAR-REACT-3[NCT00262054] | Phase 4 | 4,570 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions[NCT00735280] | Phase 4 | 2,505 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| A Multicenter, Randomized, Controlled, Double-Blind Trial to Investigate the Clinical Efficacy and Tolerability of Early Treatment With Simvastatin 40 mg Daily for 30 Days, Followed by Simvastatin 80 mg Daily Thereafter in Tirofiban-Treated Acute Coronary[NCT00251576] | Phase 3 | 4,497 participants (Actual) | Interventional | 1999-11-01 | Completed | ||
| Laboratory Implications of Non Obstructive Atherosclerotic Plaques Identified by Multiple Detector Coronary Angiotomography[NCT03632785] | 90 participants (Actual) | Observational | 2017-03-27 | Completed | |||
| A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)[NCT00140465] | Phase 4 | 60 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309] | 30 participants (Anticipated) | Interventional | 2006-04-30 | Completed | |||
| Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention[NCT03145675] | Phase 4 | 378 participants (Actual) | Interventional | 2017-05-12 | Completed | ||
| Anti-Xa Assay Correlation to the Efficacy and Safety of Enoxaparin in the Treatment of Pulmonary Embolism[NCT02977013] | 42 participants (Actual) | Observational | 2013-08-31 | Completed | |||
| Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423] | Phase 2 | 113 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Segment Elevation Myocardial Infarction The Eindhoven Reperfusion Study[NCT00986050] | Phase 4 | 907 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261] | Phase 4 | 1,001 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273] | 1,800 participants (Anticipated) | Observational [Patient Registry] | 2018-11-21 | Not yet recruiting | |||
| [NCT00000614] | Phase 3 | 0 participants | Interventional | 1998-09-30 | Completed | ||
| Influence of the Compression Method After Transradial Catheterization in Radial Artery[NCT02697526] | 274 participants (Actual) | Interventional | 2007-01-31 | Completed | |||
| The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093] | 280 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention[NCT00097591] | Phase 3 | 13,619 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Uninterrupted Direct-acting Oral Anticoagulation in Patients Undergoing Transradial Percutaneous Coronary Procedures[NCT05292846] | Phase 4 | 200 participants (Anticipated) | Interventional | 2022-01-20 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The percentage of participants is the total number of participants experiencing an all-cause death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.61 |
| Prasugrel: 75 Years of Age or Older | 27.04 |
| Clopidogrel: <75 Years of Age | 11.12 |
| Clopidogrel: 75 Years of Age or Older | 26.83 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.06 |
| Prasugrel: 75 Years of Age or Older | 24.64 |
| Clopidogrel: <75 Years of Age | 10.96 |
| Clopidogrel: 75 Years of Age or Older | 24.13 |
The percentage of participants is the total number of participants experiencing a CV death or nonfatal MI divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 9.61 |
| Prasugrel: 75 Years of Age or Older | 22.53 |
| Clopidogrel: <75 Years of Age | 10.21 |
| Clopidogrel: 75 Years of Age or Older | 22.69 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, nonfatal stroke or re-hospitalization for a recurrent UA divided by number of participants in the treatment arm. Endpoints events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 12.13 |
| Prasugrel: 75 Years of Age or Older | 26.27 |
| Clopidogrel: <75 Years of Age | 12.83 |
| Clopidogrel: 75 Years of Age or Older | 25.67 |
Brain natriuretic peptide (BNP) is secreted by the ventricles of the heart in response to hemodynamic stress and is a biomarker associated with increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 6 Months
| Intervention | picograms per milliliter (pg/mL) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=725, 125, 701, 174) | |
| Clopidogrel: <75 Years of Age | 319.345 | 250.982 |
| Clopidogrel: 75 Years of Age or Older | 951.359 | 722.750 |
| Prasugrel: <75 Years of Age | 313.494 | 253.434 |
| Prasugrel: 75 Years of Age or Older | 1082.396 | 770.132 |
C-Reactive Protein (CRP) is a biomarker associated with inflammation and increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and Month 6
| Intervention | milligrams per liter (mg/L) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=755, 143, 745, 178) | |
| Clopidogrel: <75 Years of Age | 2.287 | 2.149 |
| Clopidogrel: 75 Years of Age or Older | 2.226 | 1.543 |
| Prasugrel: <75 Years of Age | 2.330 | 2.272 |
| Prasugrel: 75 Years of Age or Older | 2.441 | 1.593 |
Seattle Angina Questionnaire (SAQ) is a validated, disease-specific questionnaire containing 11 questions (Q) yielding 5 summary scales related to angina: physical limitations, angina stability, angina frequency, treatment satisfaction and disease perception. In this study only angina frequency and the physical limitations scales were assessed. Anginal Frequency was assessed using Q3 and Q4 which consists of a Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how often a patient is having symptoms now. Physical limitations was assessed using Q1 which contains 9 items each assessed via Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how much a participant's condition is hampering their ability to do what they want to do. Scale scores are transformed to a 0-100 by subtracting the lowest possible score, dividing by the range of the scale, and multiplying by 100. Higher values equal better quality of life. (NCT00699998)
Timeframe: Baseline and follow-up (24 months)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline, physical limitations | Baseline, angina frequency | 24 Months, physical limitations (n=420, 412) | 24 Months, angina frequency (n=420, 412) | |
| Clopidogrel | 67.0 | 73.1 | 74.5 | 89.5 |
| Prasugrel | 67.8 | 73.6 | 75.1 | 89.7 |
Variation in the genes encoding the cytochrome P450 (CYP) enzymes (CYP2C19) can reduce the ability to metabolize clopidogrel and a reduced platelet response and have been associated with increased rates of CV events including CV death. Participants were classified as extensive metabolizers (EM); reduced metabolizers (RM); or unknown (UNK) metabolizers based on their CYP2C19 genotype. Possible extensive metabolizer (EM) phenotypes include EM=extensive metabolizer, UM=ultra-rapid metabolizer, and EM (non-UM) that are not UM. Possible reduced metabolizer (RM) phenotypes include IM=intermediate metabolizer and PM=poor metabolizer. Genotypes associated with each predicted phenotype are presented; predicted phenotype is presented first followed by the genotype. Percentage=(number of participants with the predicted phenotype and genotype divided by the total number of participants per arm) multiplied by 100. (NCT00699998)
Timeframe: Baseline
| Intervention | percentage participants with geneotype (Number) | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UM, *1/*17 | UM, *17/*17 | EM (non-UM), *1/*1 | IM, *1/*2 | IM, *1/*3 | IM, *1/*4 | IM, *1/*6 | IM, *1/*8 | PM, *2/*2 | PM, *2/*3 | PM, *2/*4 | PM, *2/*6 | PM, *2/*8 | PM, *3/*3 | UNK, *1/*10 | UNK, *1/*13 | UNK, *1/*9 | UNK, *1/*9, *9/*17 | UNK, *13/*17 | UNK, *2/*13 | UNK, *2/*17 | UNK, *2/*9 | UNK, *3/*17 | UNK, *4/*17 | UNK, *4/*9 | UNK, *6/*17 | UNK, *8/*17 | UNK, *9/*17 | UNK, Undefined genotype | |
| Clopidogrel: <75 Years of Age | 25.1 | 5.4 | 35.7 | 19.8 | 0.5 | 0.1 | 0.0 | 0.4 | 4.3 | 0.3 | 0.2 | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.8 | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | 0.5 |
| Clopidogrel: 75 Years of Age or Older | 21.8 | 4.3 | 41.2 | 19.7 | 0.6 | 0.3 | 0.2 | 0.3 | 3.8 | 0.3 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.2 | 0.0 | 0.3 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.6 |
| Prasugrel: <75 Years of Age | 24.0 | 5.1 | 38.8 | 18.6 | 0.8 | 0.4 | 0.0 | 0.1 | 3.9 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 6.3 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.7 |
| Prasugrel: 75 Years of Age or Older | 25.0 | 3.6 | 42.1 | 18.3 | 0.6 | 0.0 | 0.2 | 0.5 | 2.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 6.1 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 |
Platelet aggregation was measured by as measured by Accumetrics Verify Now™ P2Y12. Results were reported in P2Y12 Reaction Units (PRU). PRU represents the rate and extent of adenosine (ADP)-stimulated platelet aggregation. Lower values indicate greater P2Y12 platelet inhibition and lower platelet activity and aggregation. ANCOVA Model was used and values were corrected for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 12 Months
| Intervention | P2Y12 Reaction Units (PRU) (Least Squares Mean) | |
|---|---|---|
| Day 30 | Month 12 (n=386, 76, 400, 103) | |
| Clopidogrel: <75 Years of Age | 193.489 | 199.003 |
| Clopidogrel: 75 Years of Age or Older | 200.285 | 181.360 |
| Prasugrel: <75 Years of Age | 93.280 | 94.529 |
| Prasugrel: 75 Years of Age or Older | 151.872 | 135.096 |
All deaths, regardless of possible relatedness, with the exception of 1 event, were adjudicated by the Clinical Endpoint Committee (CEC) and are reported in this table. The 1 event which was not adjudicated was a result of the revocation of consent by the participant prior to their death. Deaths possibly related to study drug in the opinion of the investigator are also contained in the Serious Adverse Event (SAE) module. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | participants (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Congestive Heart Failure | Cardiogenic Shock | Cardiac Rupture | Myocardial Infarction | Dysrhythmia | Stent Thrombosis | Directly Related to Revascularization-CABG or PCI | Intracranial Hemorrhage | Non-Hemorrhagic Stroke | Sudden death due to cardiovascular event | Pulmonary Embolism | Stroke, unknown type | Other Cardiovascular Event | Cardiovascular event, unknown type | Accidental | Trauma | Hemorrhage, not intracranial | Infection | Malignancy | Suicide | Other Non-Cardiovascular event | Cause unknown (nonadjudicated event) | |
| Clopidogrel: <75 Years of Age | 13 | 10 | 0 | 24 | 6 | 0 | 1 | 4 | 4 | 70 | 2 | 0 | 0 | 45 | 1 | 0 | 0 | 16 | 14 | 0 | 8 | 0 |
| Clopidogrel: 75 Years of Age or Older | 23 | 9 | 0 | 21 | 3 | 0 | 1 | 1 | 3 | 43 | 1 | 0 | 1 | 45 | 1 | 1 | 4 | 17 | 11 | 0 | 6 | 0 |
| Prasugrel: <75 Years of Age | 10 | 8 | 0 | 16 | 5 | 0 | 1 | 2 | 4 | 75 | 0 | 0 | 6 | 40 | 1 | 2 | 1 | 14 | 14 | 1 | 8 | 0 |
| Prasugrel: 75 Years of Age or Older | 21 | 4 | 1 | 24 | 2 | 0 | 1 | 1 | 4 | 39 | 1 | 1 | 1 | 41 | 0 | 3 | 1 | 21 | 7 | 0 | 4 | 1 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 4 |
| Placebo | 5 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 1 |
| Placebo | 0 |
Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery
| Intervention | percentage (Number) |
|---|---|
| 75mg Clopidogrel | 94.3 |
| Placebo | 93.2 |
IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery
| Intervention | mm (Mean) |
|---|---|
| 75mg Clopidogrel | 4.1 |
| Placebo | 4.5 |
The endpoint in this measure is a combination of all-cause death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 692 |
| Clopidogrel | 822 |
The endpoint in this measure is a combination of CV death, nonfatal MI, nonfatal stroke, or rehospitalization for cardiac ischemic events. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 797 |
| Clopidogrel | 938 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 502 | 573 |
| Prasugrel | 389 | 462 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI). (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) | ||
|---|---|---|---|
| UA/NSTEMI (n=5044, n=5030) | STEMI (n=1769, n=1765) | All ACS (n=6813, n=6795) | |
| Clopidogrel | 565 | 216 | 781 |
| Prasugrel | 469 | 174 | 643 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or UTVR. Results are reported for the All ACS subject population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 504 | 588 |
| Prasugrel | 399 | 472 |
TIMI classification for major and minor bleeding in the subset of subjects who did not undergo a coronary artery bypass operation (CABG) were defined as follows: Major bleeding: any intracranial hemorrhage (ICH) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL)from baseline. Minor Bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 gm/dL but <5 gm/dL from baseline. Major bleeding events were further examined as events that were deemed life threatening and/or fatal. (NCT00097591)
Timeframe: First dose of study drug up to 15 months (while at risk)
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| TIMI Major or Minor Bleeding | TIMI Major Bleeding | TIMI Major Bleeding - Life-threatening (LT) | LT - Fatal | LT - Symptomatic intracranial hemorrage (ICH) | LT - Requiring inotropes | LT - Requiring surgical intervention | LT - Requiring transfusion (>=4 units) | TIMI Minor Bleeding | |
| Clopidogrel | 231 | 111 | 56 | 5 | 17 | 8 | 19 | 30 | 125 |
| Prasugrel | 303 | 146 | 85 | 21 | 19 | 21 | 19 | 45 | 164 |
63 reviews available for ticlopidine and Angina, Unstable
| Article | Year |
|---|---|
Use of antiplatelet drugs in the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Clinical Trials as Topi | 2013 |
[Differentiated antiplatelet therapy for acute coronary syndromes].
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrh | 2014 |
Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE): updated standing orders for ST-segment elevation myocardial infarction and unstable angina/non-ST-segment elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogr | 2010 |
[Platelet inhibition with prasugrel].
Topics: Acute Coronary Syndrome; Administration, Oral; Angina, Unstable; Biological Availability; Clopidogre | 2010 |
Unstable angina and non-ST elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary | 2012 |
Unstable angina.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin, Low-Molecular-We | 2002 |
[Treatment strategy of unstable angina and non-ST-segment elevation myocardial infarction].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Coronary Angiography; | 2002 |
Unstable angina.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin, Low-Molecular-We | 2002 |
2002 update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: implications for emergency department practice.
Topics: American Heart Association; Angina, Unstable; Anticoagulants; Cardiology; Child; Clopidogrel; Electr | 2003 |
Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.
Topics: Acute Disease; Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clop | 2003 |
Appropriate antiplatelet and antithrombotic therapy in patients with acute coronary syndromes: recent updates to the ACC/AHA guidelines.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopid | 2002 |
Clopidogrel in acute coronary syndromes (unstable angina and non-Q-wave myocardial infarction).
Topics: Angina, Unstable; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Platelet Agg | 2003 |
Emergency management of hemorrhagic complications in the era of glycoprotein IIb/IIIa receptor antagonists, clopidogrel, low molecular weight heparin, and third-generation fibrinolytic agents.
Topics: Acute Disease; Angina, Unstable; Clopidogrel; Emergency Medical Services; Fibrinolytic Agents; Hemor | 2003 |
[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].
Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Antibodies, Monoclonal; Ant | 2003 |
Angina (unstable).
Topics: Angina, Unstable; Aspirin; Clopidogrel; Heparin, Low-Molecular-Weight; Humans; Platelet Aggregation | 2003 |
The role of clopidogrel in the management of acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; C | 2003 |
Treatment of unstable angina pectoris/non-ST-segment elevation myocardial infarction in elderly patients.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Antic | 2003 |
Recent clinical trial results with antiplatelet therapy: implications in stroke prevention.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Pla | 2004 |
[Drug therapy for patients with unstable angina].
Topics: Abciximab; Adrenergic beta-Antagonists; Angina, Unstable; Antibodies, Monoclonal; Aspirin; Calcium C | 2004 |
Clopidogrel's role in the management of atherosclerotic disease: a focus on acute coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Clinical Trials as Topi | 2003 |
Acute coronary syndromes in women: is treatment different? Should it be?
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Female; Fibri | 2004 |
P2Y12, a new platelet ADP receptor, target of clopidogrel.
Topics: Adenosine Diphosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Down-Regulation; Hum | 2003 |
Combined antithrombotic therapy for acute coronary syndrome.
Topics: Administration, Oral; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; D | 2003 |
Role of clopidogrel in unstable angina and non-ST-segment elevation myocardial infarction: from literature and guidelines to practice.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Hemorrhage; Humans; | 2004 |
Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Comorbidity; Diabetes Mellitus; Humans; Hypercholesterolemia | 2004 |
Platelet function testing in cardiovascular diseases.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Case Management; Clopidogrel; Drug Resistance; H | 2004 |
Angina (unstable).
Topics: Angina, Unstable; Aspirin; Cardiac Catheterization; Heparin, Low-Molecular-Weight; Humans; Platelet | 2003 |
Issues in the management of antiplatelet therapy in patients undergoing surgical revascularization. A roundtable discussion.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; C | 2005 |
Clopidogrel in acute coronary syndrome: when, how much, how long?
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; D | 2005 |
Best evidence topic report. Clopidogrel plus aspirin or aspirin alone in unstable angina.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhi | 2006 |
[Secondary prevention of acute coronary syndromes: are we following correctly the guidelines?].
Topics: Acute Disease; Adrenergic beta-Antagonists; Algorithms; Angina, Unstable; Angiotensin-Converting Enz | 2006 |
[Anti-platelet drugs (aspirin, ticlopidine, etc)].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Humans; Meta-An | 2006 |
Angina (unstable).
Topics: Angina, Unstable; Aspirin; Cardiac Catheterization; Clopidogrel; Heparin, Low-Molecular-Weight; Huma | 2005 |
Multiple coronary thrombosis and stent implantation to the subtotally occluded right renal artery in a patient with essential thrombocytosis: a case report with review.
Topics: Angina, Unstable; Angioplasty; Clopidogrel; Coronary Thrombosis; Female; Humans; Hypertension; Middl | 2006 |
The year in non-ST-segment elevation acute coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Clopidogrel; Coronary Ve | 2006 |
Platelet P2 receptors: old and new targets for antithrombotic drugs.
Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Coronar | 2007 |
The role of clopidogrel in revascularized and nonrevascularized patients with acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass | 2007 |
Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease.
Topics: Angina, Unstable; Aspirin; Atherosclerosis; Biomarkers; Blood Platelets; Clopidogrel; Humans; Inflam | 2007 |
Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Th | 2007 |
Aspirin combined with clopidogrel (Plavix) decreases cardiovascular events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Evidence-B | 2007 |
Translational therapeutics at the platelet vascular interface. Summary.
Topics: Angina, Unstable; Animals; Aspirin; Blood Platelets; Clopidogrel; Disease Models, Animal; Drug Evalu | 2008 |
[Blood platelet aggregation inhibitors in the treatment of heart diseases].
Topics: Angina, Unstable; Aspirin; Coronary Artery Disease; Coronary Disease; Dipyridamole; Humans; Platelet | 1993 |
Platelet activation and inhibition in unstable coronary syndromes.
Topics: Angina, Unstable; Aspirin; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation | 1997 |
[Antithrombotic agents in unstable angina. Review of clinical trials].
Topics: Angina, Unstable; Aspirin; Clopidogrel; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hirudin | 1998 |
Low molecular weight heparins in the cardiac catheterization laboratory.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; | 1999 |
Management of high-risk subsets in unstable angina.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Atherectomy, Coronary; Calcium Channel Bl | 1999 |
[Current therapy for unstable angina pectoris].
Topics: Angina, Unstable; Anti-Bacterial Agents; Anticholesteremic Agents; Anticoagulants; Antithrombins; As | 1999 |
Ticlopidine and clopidogrel.
Topics: Adenosine Diphosphate; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Angina, Unstable; Aspirin; Bo | 1999 |
[Intervention therapy of acute coronary syndrome].
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; | 1999 |
Beyond heparin and aspirin: new treatments for unstable angina and non-Q-wave myocardial infarction.
Topics: Angina, Unstable; Antithrombins; Clopidogrel; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hi | 2000 |
Treatment of unstable angina: the role of platelet inhibitors and anticoagulants.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Clopidogrel; Coronary Thrombosi | 1999 |
[Therapeutic inhibition of platelets in a acute coronary syndrome and in coronary intervention: mechanisms and clinical results].
Topics: Abciximab; Acute Disease; Adult; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; | 2000 |
The future of antiplatelet therapy: optimizing management in patients with acute coronary syndrome.
Topics: Angina, Unstable; Clopidogrel; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregat | 2000 |
[Acute coronary syndromes: an update. I. Pathogenesis and drug therapy].
Topics: Acute Disease; Administration, Oral; Adrenergic beta-Antagonists; Angina, Unstable; Anticoagulants; | 2001 |
Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Heparin; Humans; Myo | 2001 |
New approaches to the pharmacological treatment of angina.
Topics: Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 2001 |
Combination therapy with clopidogrel and aspirin: can the CURE results be extrapolated to cerebrovascula patients?
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; | 2001 |
From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Heparin; Humans; Intracranial Art | 2002 |
Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Thrombosis; Heparin, Low-Molecular-Weight; Humans; | 2002 |
[Modern therapy in acute coronary syndrome].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Di | 2002 |
Clinical pharmacology of bivalirudin.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Clinical Trials as | 2002 |
Antiplatelet treatment in unstable angina: aspirin, clopidogrel, glycoprotein IIb/IIIa antagonist, or all three?
Topics: Administration, Oral; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Costs; | 2002 |
Is CURE a cure for acute coronary syndromes? Statistical versus clinical significance.
Topics: Acute Disease; Angina, Unstable; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Platelet | 2002 |
62 trials available for ticlopidine and Angina, Unstable
| Article | Year |
|---|---|
Prasugrel as opposed to clopidogrel improves endothelial nitric oxide bioavailability and reduces platelet-leukocyte interaction in patients with unstable angina pectoris: A randomized controlled trial.
Topics: Aged; Angina, Unstable; Biological Availability; Blood Platelets; Clopidogrel; Double-Blind Method; | 2017 |
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Clopidogrel; Coronary Angiography; Female; Humans; | 2013 |
[The effect of clopidogrel and aspigrel on myocardial ischemia in patients with unstable angina pectoris].
Topics: Aged; Angina, Unstable; Aspirin; Clopidogrel; Drug Combinations; Drug Therapy, Combination; Humans; | 2013 |
Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial.
Topics: Angina, Unstable; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; M | 2014 |
Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial.
Topics: Aged; Angina, Unstable; Clopidogrel; Endpoint Determination; Humans; Middle Aged; Myocardial Infarct | 2015 |
Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acu
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Clopidogrel; Coronary Angiography; Double-Blind Met | 2015 |
Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Biomarkers; Cholesterol, HDL; Clopidogrel; | 2016 |
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel | 2008 |
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel | 2008 |
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel | 2008 |
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel | 2008 |
Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Su
Topics: Aged; Aged, 80 and over; Angina, Unstable; Clopidogrel; Electrocardiography; Female; Hemorrhage; Hos | 2008 |
Aprotinin for patients exposed to clopidogrel before off-pump coronary bypass.
Topics: Adult; Aged; Angina, Unstable; Aprotinin; Blood Transfusion; Chest Tubes; Clopidogrel; Coronary Arte | 2008 |
Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; | 2009 |
Timing of clopidogrel loading before percutaneous coronary intervention in clopidogrel-naive patients with stable or unstable angina: a comparison of two strategies.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; C-Reactive Protein; Clopido | 2009 |
5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary
Topics: Abciximab; Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Angina, Unstable; An | 2010 |
Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data.
Topics: Aged; Angina, Unstable; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cohort Studies; Cytochrome P-450 | 2010 |
Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage
Topics: Administration, Oral; Aged; Angina, Unstable; Clopidogrel; Dose-Response Relationship, Drug; Double- | 2010 |
Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events trial and the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascula
Topics: Adult; Aged; Angina, Unstable; Aryldialkylphosphatase; Atrial Fibrillation; Clopidogrel; Female; Hum | 2012 |
[Changes in coagulation and fibrinolysis in the patients with coronary heart disease in acute period and effect of drug intervention].
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Blood Coagulation; Case-Control Studies; | 2012 |
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Doub | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Oral antiplatelet therapies have no effect on circulating levels of RANTES in patients with coronary artery disease.
Topics: Aged; Angina, Unstable; Chemokine CCL5; Chemokines; Clopidogrel; Coronary Artery Disease; Female; He | 2002 |
Early and late effects of clopidogrel in patients with acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combinatio | 2003 |
The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Heart Failure | 2003 |
Parameters of the tissue factor pathway with coumadin/dipyridamole versus ticlopidine as adjunct antithrombotic-drug regimen in coronary artery stenting.
Topics: Adult; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; C | 2003 |
Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blin | 2003 |
Prediction of significant left main coronary artery stenosis by the 12-lead electrocardiogram in patients with rest angina pectoris and the withholding of clopidogrel therapy.
Topics: Adult; Aged; Angina, Unstable; Clopidogrel; Coronary Angiography; Coronary Stenosis; Electrocardiogr | 2003 |
[Non ST elevation acute coronary syndrome. Some characteristics of coagulation and von Willebrand factor during short term use of ticlopidine or clopidogrel].
Topics: Acute Disease; Adult; Angina, Unstable; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; Dat | 2003 |
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter | 2004 |
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter | 2004 |
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter | 2004 |
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter | 2004 |
Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
Topics: Acute Disease; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2004 |
The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study.
Topics: Angina, Unstable; Canada; Clopidogrel; Cost-Benefit Analysis; Europe; Health Care Costs; Hospitaliza | 2004 |
Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome.
Topics: Aged; Angina, Unstable; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug In | 2005 |
One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel.
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagu | 2005 |
Comparison of two strategies for the management of antiplatelet therapy during urgent surgery.
Topics: Aged; Angina, Unstable; Aprotinin; Aspirin; Clopidogrel; Coronary Artery Bypass; Female; Hemostatics | 2005 |
Prospective randomized comparison of early and late results of a carbonized stent versus a high-grade stainless steel stent of identical design: the PREVENT Trial [corrected].
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biocompatibl | 2005 |
Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: a double-blind, placebo-controlled, randomized clinical trial.
Topics: Aged; Angina, Unstable; Anticoagulants; Aprotinin; Blood Transfusion; Clopidogrel; Coronary Artery B | 2005 |
Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstrea
Topics: Abciximab; Acute Disease; Aged; Angina, Unstable; Antibodies, Monoclonal; Clopidogrel; Creatine Kina | 2005 |
Effects of clopidogrel on the rebound hypercoagulable state after heparin discontinuation in patients with acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Antithrombin III; Clopidogrel; Heparin; Humans; Myo | 2005 |
Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Coronary Dise | 2005 |
Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome.
Topics: Adult; Aged; Angina, Unstable; Aspirin; C-Reactive Protein; Clopidogrel; Drug Therapy, Combination; | 2006 |
Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
Topics: Acute Disease; Aged; Angina, Unstable; Aspirin; C-Reactive Protein; CD40 Ligand; Clopidogrel; Dose-R | 2006 |
Erythrocyte deformability and white blood cell count are associated with aspirin resistance in high-risk vascular patients.
Topics: Aged; Angina, Unstable; Aspirin; Bleeding Time; Blood Viscosity; Clopidogrel; Drug Resistance; Eryth | 2006 |
The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Follow-Up | 2006 |
Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy).
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Corona | 2007 |
[The effect of different loading doses of clopidogrel on platelet aggregation].
Topics: Adult; Aged; Angina, Unstable; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; | 2007 |
Renal function and outcomes in acute coronary syndrome: impact of clopidogrel.
Topics: Aged; Angina, Unstable; Clopidogrel; Coronary Disease; Creatinine; Double-Blind Method; Female; Glom | 2007 |
Optimal platelet inhibition in patients undergoing PCI: data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Eptifibatide; Humans; Myocardial Infa | 2007 |
Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Canada; Cl | 2007 |
[Unstable angina: efficacy and tolerability of therapy with aspirin and aspirin combined with ticlopidine].
Topics: Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Disease Progression; Drug Therap | 2007 |
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Com | 2008 |
[Ticlopidine and aspirin in the treatment of unstable angina: comparative evaluation of their effect of anti-aggregation and platelet membranes].
Topics: Adult; Aged; Angina, Unstable; Anti-Arrhythmia Agents; Aspirin; Cholesterol; Heparin; Humans; Male; | 1993 |
Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)
Topics: Adult; Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspi | 1998 |
[Antithrombotic agents in unstable angina. Review of clinical trials].
Topics: Angina, Unstable; Aspirin; Clopidogrel; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hirudin | 1998 |
[Effectiveness of unstable angina pectoris treatment by aggregation inhibitors ticlid and aspirin].
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Electrocardiography, Ambulatory; Female; | 1998 |
[Clinical effectiveness and specific action of antiaggregants in patients with unstable angina].
Topics: Angina, Unstable; Aspirin; Electrocardiography, Ambulatory; Female; Hemostasis; Humans; Male; Middle | 2000 |
Effect of aspirin and ticlopidine on plasma tissue factor levels in stable and unstable angina pectoris.
Topics: Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Antithrombin III; Aspirin; Athere | 2000 |
The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Humans; Meta-Analysis as Topic; Platelet Aggregation Inhibit | 2000 |
[Lectin-induced platelet aggregation inpatients with unstable angina pectoris treated with anti-aggregation agents].
Topics: Adenosine Monophosphate; Angina, Unstable; Blood Platelets; Female; Humans; Lectins; Male; Middle Ag | 2001 |
Insights from CURE: using clopidogrel on top of standard therapy.
Topics: Aged; Angina, Unstable; Aspirin; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Hepari | 2002 |
[Comparative efficacy of tiklid and aspirin in patients with unstable angina].
Topics: Angina, Unstable; Aspirin; Blood Coagulation; Endothelium, Vascular; Female; Fibrinolytic Agents; Hu | 2001 |
Ticlopidine treatment for patients with unstable angina at rest. A further analysis of the study of ticlopidine in unstable angina. Studio della Ticlopidina nell'Angina Instabile Group.
Topics: Aged; Angina, Unstable; Humans; Male; Middle Aged; Myocardial Infarction; Rest; Ticlopidine | 1991 |
Ticlopidine in unstable angina. A more expensive aspirin?
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Cost-Benefit Analysis; Cycloox | 1990 |
Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group.
Topics: Angina Pectoris; Angina, Unstable; Female; Humans; Male; Multicenter Studies as Topic; Patient Dropo | 1990 |
Ticlopidine in unstable angina.
Topics: Angina, Unstable; Aspirin; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 1990 |
119 other studies available for ticlopidine and Angina, Unstable
| Article | Year |
|---|---|
Newly identified synergy between clopidogrel and calcium-channel blockers for blood pressure regulation possibly involves CYP2C19 rs4244285.
Topics: Adult; Aged; Angina, Unstable; Aryl Hydrocarbon Hydroxylases; Blood Pressure; Calcium Channel Blocke | 2013 |
[Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
Topics: Acute Coronary Syndrome; Aged; Alleles; Angina, Unstable; Aryldialkylphosphatase; Biotransformation; | 2014 |
TRILOGY ACS: prasugrel of benefit only after angiography?
Topics: Angina, Unstable; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Ag | 2013 |
PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity.
Topics: Angina, Unstable; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Blood Platelets; Clopidogre | 2013 |
[What kind of antiplatelet treatment in acute coronary syndrome?--Intensive antiplatelet treatment only for patients with invasive strategy].
Topics: Angina, Unstable; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inh | 2013 |
We need to do better for patients with non-ST-segment elevation acute coronary syndrome who are managed without revascularization.
Topics: Angina, Unstable; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inh | 2014 |
Comparative effectiveness of clopidogrel in medically managed patients with unstable angina and non-ST-segment elevation myocardial infarction.
Topics: Aged; Angina, Unstable; Clopidogrel; Cohort Studies; Disease Management; Female; Follow-Up Studies; | 2014 |
Reanalysis or redefinition of the hypothesis?
Topics: Angina, Unstable; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasu | 2015 |
Acute coronary syndromes and coronary intervention.
Topics: Angina, Unstable; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasu | 2015 |
Another side effect of ticagrelor: Atrial fibrillation.
Topics: Adenosine; Aged; Angina, Unstable; Atrial Fibrillation; Clopidogrel; Humans; Male; Ticagrelor; Ticlo | 2016 |
Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy | 2016 |
2007 Guideline update for unstable angina/non-ST-segment elevation myocardial infarction: focus on antiplatelet and anticoagulant therapies.
Topics: American Heart Association; Angina, Unstable; Anticoagulants; Clopidogrel; Drug-Eluting Stents; Enox | 2008 |
[Acute coronary syndrome -- long term protection by dual thrombocyte aggregation inhibition during twelve months].
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials | 2008 |
Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Clopido | 2009 |
Combined carotid stenting and urgent coronary artery surgery in unstable angina patients with severe carotid stenosis.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon; Anticoagulants; Aspirin; Carotid St | 2009 |
Drug-eluting coronary stents: many meta-analyses, little benefit.
Topics: Angina, Unstable; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Co | 2009 |
Significantly lower incidence of early definite stent thrombosis of drug-eluting stents after unrestricted use in Japan using ticlopidine compared to western countries using clopidogrel: a retrospective comparison with western mega-studies.
Topics: Acute Coronary Syndrome; Angina, Unstable; Clinical Trials as Topic; Drug-Eluting Stents; Europe; Hu | 2009 |
Anxiety is a better predictor of platelet reactivity in coronary artery disease patients than depression.
Topics: Adenosine Diphosphate; Aged; Angina, Unstable; Anxiety Disorders; Aspirin; Clopidogrel; Cross-Sectio | 2010 |
Antiplatelet therapy with clopidogrel or ticlopidine reduces intimal hyperplasia in an animal model of experimental arterial injury.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Arteries; Cell Division; Clopidogrel; Cor | 2010 |
The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting.
Topics: Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; | 2010 |
[Managing myocardial infarct in general practice].
Topics: Acute Coronary Syndrome; Algorithms; Angina, Unstable; Anticoagulants; Atorvastatin; Blood Chemical | 2010 |
[Registries of myocardial infarction in Germany. Consequences for drug therapy of patients with acute ST elevation myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Corona | 2010 |
Mid-term outcomes of patients with PCI prior to CABG in comparison to patients with primary CABG.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Case-Control Studies; Clopidogrel; Coronary | 2010 |
Increased use of acid-suppressing drugs before the occurrence of ischemic events: a potential source of confounding in recent observational studies.
Topics: Adult; Aged; Angina, Unstable; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Confounding Fac | 2010 |
Dosing of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Algorithms; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clop | 2010 |
Influence of updated guidelines on short- and long-term mortality in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS).
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Clopidogrel; Female; Follow-Up S | 2012 |
Aneurysm formation after drug-eluting balloon treatment of drug-eluting in-stent restenosis: first case report.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheters; Cardiovascular Agents; | 2012 |
Paraoxonase 1 Q192R variant and clopidogrel efficacy: fact or fiction?
Topics: Angina, Unstable; Aryldialkylphosphatase; Atrial Fibrillation; Clopidogrel; Female; Humans; Male; Po | 2012 |
Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Clopidogrel; Computer Simulation; Cost-Ben | 2012 |
Multiple comparisons of drug efficacy between subgroups defined by genetic polymorphisms.
Topics: Alleles; Angina, Unstable; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Hum | 2012 |
Prasugrel versus clopidogrel for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angina, Unstable; Female; Humans; Male; Myocardial Infarction; Piperazines; | 2013 |
Prasugrel versus clopidogrel for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angina, Unstable; Female; Humans; Male; Myocardial Infarction; Piperazines; | 2013 |
[2002 Update of the Guidelines of the Spanish Society of Cardiology for Unstable Angina/Without ST-Segment Elevation Myocardial Infarction].
Topics: Angina, Unstable; Chest Pain; Clopidogrel; Electrocardiography; Heparin, Low-Molecular-Weight; Human | 2002 |
[New US guidelines. Myocardial infarct is now treated more aggressively].
Topics: Angina, Unstable; Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Humans; Myoc | 2002 |
New guidelines for unstable angina. What you and your doctor need to know when chest pain worsens.
Topics: Angina, Unstable; Clinical Competence; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Hu | 2002 |
ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidel
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; | 2002 |
Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Hemorrhage | 2002 |
Clopidogrel plus aspirin for stroke prevention.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Follow- | 2002 |
A partial CURE for acute coronary syndromes--but how did it happen?
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Platele | 2002 |
[Indications of treatment with clopidogrel in the guidelines of the Spanish Society of Cardiology for unstable angina/non-ST-segment elevation acute myocardial infarction].
Topics: Angina, Unstable; Clopidogrel; Electrocardiography; Humans; Myocardial Infarction; Platelet Aggregat | 2002 |
Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cor | 2002 |
New treatment guidelines for unstable angina/non-ST-segment elevation myocardial infartion.
Topics: Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Heparin, Low-Molecu | 2002 |
[New guidelines in acute coronary syndrome. Clopidogrel for nine months is recommended].
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hum | 2002 |
[In acute coronary syndrome. Seize platelets with pliers].
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclooxygenase Inhi | 2002 |
Pharmacological treatment of acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Clopidogrel; Humans; Myocardial Infarction; | 2003 |
Spontaneous hemarthrosis of the knee associated with clopidogrel and aspirin treatment.
Topics: Aged; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Coagulation Tests; C | 2003 |
Introduction to "Optimizing management of non-ST-segment elevation acute coronary syndromes". Harmonizing advances in mechanical and pharmacologic intervention.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Clopidogre | 2003 |
Statistical versus clinical significance of the CURE study in acute coronary syndromes.
Topics: Angina, Unstable; Clinical Trials as Topic; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggr | 2003 |
Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina?
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Logistic Models; Male | 2003 |
[Acute coronary syndrome. The second platelet inhibitor is self-paid].
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analys | 2003 |
[Premedication by thienopyridine before percutaneous coronary interventions in unstable angina].
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Fibrinolytic Agents; Fo | 2003 |
[Dual platelet inhibition with clopidogrel and ASS. Who profits from the combination?].
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclooxygenase Inhi | 2003 |
Antiplatelet therapy for ischemic heart disease.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopid | 2004 |
Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2004 |
Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes.
Topics: Analysis of Variance; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Cardiac Cath | 2004 |
Long-term management of patients with unstable angina and non-ST-elevation MI.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Evidence-Based Medicine; Humans; Hydroxymethylglutaryl-CoA R | 2004 |
Building evidence for early initiation of clopidogrel loading in non-ST-segment elevation acute coronary syndromes: going past the American College of Cardiology/American Heart Association guidelines.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; E | 2004 |
[Cost effectiveness of clopidogrel in acute coronary syndromes without ST-elevation (unstable angina, non-Q AMI)].
Topics: Acute Disease; Angina, Unstable; Canada; Cardiology; Clopidogrel; Congresses as Topic; Cost-Benefit | 2004 |
[Guidelines: acute coronary syndrome (ACS)].
Topics: Acute Disease; Angina, Unstable; Clinical Trials as Topic; Clopidogrel; Coronary Angiography; Electr | 2004 |
[Combination is standard. Dual thrombocyte function inhibition in acute coronary syndrome].
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; | 2004 |
[Interview with Prof. Dr. H. J. Rupprecht about secondary prevention: what is the optimal thrombocyte function inhibition?].
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Long-Term Care; Myocardia | 2004 |
Clopidogrel resistance.
Topics: Angina, Unstable; Clopidogrel; Drug Resistance; Humans; Platelet Aggregation; Platelet Aggregation I | 2004 |
Severe stenosis of anastomoses by using the symmetry aortic connector system.
Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Arter | 2004 |
Development of a score to predict the need for coronary artery bypass graft surgery in patients with non-ST segment elevation acute coronary syndromes.
Topics: Aged; Angina, Unstable; Clopidogrel; Coronary Artery Bypass; Heart Failure; Humans; Logistic Models; | 2004 |
Subacute coronary stent thrombosis in a patient developing clopidogrel associated thrombotic thrombocytopenic purpura.
Topics: Aged; Angina, Unstable; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis | 2005 |
Long-term combination therapy with aspirin and clopidogrel.
Topics: Angina, Unstable; Arteriosclerosis; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Double-Blind Me | 2004 |
Summaries for patients. Is it cost-effective to treat high-risk cardiac patients with clopidogrel plus aspirin as opposed to aspirin alone?
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A | 2005 |
A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A | 2005 |
Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry.
Topics: Adolescent; Adult; Aged; Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; | 2005 |
Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; | 2004 |
Cost of care for new-onset acute coronary syndrome patients who undergo coronary revascularization.
Topics: Acute Disease; Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Angina, Unstable; Clopidogrel; | 2005 |
Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting.
Topics: Abciximab; Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Mono | 2005 |
Stent thrombosis in patients treated with thienopyridines: clinical description of 10 cases.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Female; Follow- | 2004 |
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Drug Therapy | 2005 |
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Drug Therapy | 2005 |
Serial changes in platelet activation in patients with unstable angina following coronary stenting: evaluation of the effects of clopidogrel loading dose in inhibiting platelet activation.
Topics: Aged; Angina, Unstable; Clopidogrel; Drug Evaluation; Elective Surgical Procedures; Female; Humans; | 2005 |
Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Cost-Benefit Ana | 2006 |
Drawbacks of nonrandomized trials in acute coronary syndromes.
Topics: Angina, Unstable; Cardiac Catheterization; Clinical Trials as Topic; Clopidogrel; Coronary Angiograp | 2006 |
Management of acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; | 2005 |
Management of acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; | 2005 |
Impact of clopidogrel on suppression of circulating levels of soluble CD40 ligand in patients with unstable angina undergoing coronary stenting.
Topics: Aged; Angina, Unstable; CD40 Ligand; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggreg | 2006 |
Potent low dose platelet inhibitory effects of clopidogrel and aspirin on coronary thrombus formation in an animal model of acute unstable angina.
Topics: Acute Disease; Angina, Unstable; Animals; Aspirin; Clopidogrel; Coronary Thrombosis; Disease Models, | 2006 |
Embedded guideline information without patient specificity in a commercial emergency department computerized order-entry system.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Clopidogrel; Decision Support Systems, Clini | 2006 |
Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge.
Topics: Aged; Angina, Unstable; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plate | 2006 |
The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart A
Topics: Aged; Angina, Unstable; Body Mass Index; Clopidogrel; Female; Guideline Adherence; Humans; Hypolipid | 2006 |
Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery.
Topics: Aged; Angina, Unstable; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Female; Guideline Ad | 2006 |
Comparison of changes in circulating platelet-derived microparticles and platelet surface P-selectin expression after coronary stent implantation.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angina, Unstable; Blood Platelets; Cell Membrane; Cor | 2006 |
[Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome].
Topics: Age Factors; Aged; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Com | 2006 |
Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Antic | 2006 |
[Beneficial effect of a loading dose of 600 mg of clopidogrel on platelet parameters in patients admitted for acute coronary syndrome].
Topics: Acute Disease; Angina, Unstable; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarcti | 2006 |
Clopidogrel in patients with acute coronary syndromes: learning from clinical practice.
Topics: Aged; Angina, Unstable; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plate | 2006 |
[Acute coronary syndrome: when an indication for clopidogrel?].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Myocardial Infarction; Platel | 2006 |
In-hospital and late outcomes after coronary stenting in patient with unstable angina and myelodysplastic syndrome.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Humans; Male; M | 2006 |
Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases.
Topics: Aged; Angina, Unstable; Cell Adhesion Molecules; Clopidogrel; Drug Resistance; Female; Flow Cytometr | 2007 |
Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative.
Topics: Acute Disease; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Dise | 2007 |
Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention.
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Cost-Benefit Analysis; F | 2007 |
Guideline-based discharge therapy for unstable angina pectoris/non-ST elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Electrocardiography; Humans; Hypolipidemic Agents; Myocardia | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Sweet and sticky: diabetic platelets, enhanced reactivity, and cardiovascular risk.
Topics: Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudden, Car | 2007 |
Temporal trends in antiplatelet/antithrombotic use in acute coronary syndromes and in-hospital major bleeding complications.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiac Catheteriza | 2007 |
[Aprotinin reduces bleeding during off-pump coronary artery bypass grafting in a patient on ticlopidine; report of a case].
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aprotinin; Blood Loss, Surgical; Coronary Ar | 2007 |
2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2008 |
Successful emergent surgical revascularization and retrieval of entrapped drug eluting stent.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Coronary Sten | 2008 |
[Antiplatelet treatment after acute and chronic ischemic heart and brain events is insufficient according to recommendations].
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Aspirin; | 2008 |
New horizons in cardiology.
Topics: Adult; Angina, Unstable; Anticoagulants; Coronary Disease; Coronary Vessels; Electrocardiography; Fe | 1984 |
[Rotablator and endoprosthesis on the left main coronary trunk].
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Atherectomy, Coronary; Coronary Disease; Fem | 1995 |
New antiplatelet agents.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopid | 1998 |
Coronary stenting in unstable angina: early and late clinical outcomes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Coronary Disease; | 1998 |
Long-term outcome in patients treated by intracoronary stenting with ticlopidine and aspirin, and deleterious prognostic role of unstable angina pectoris.
Topics: Aged; Angina, Unstable; Aspirin; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; | 2000 |
Hemolytic uremic syndrome associated with clopidogrel: a case report.
Topics: Angina, Unstable; Clopidogrel; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Plasmapheresis; | 2000 |
Unstable angina pectoris.
Topics: Angina, Unstable; Aspirin; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2000 |
Unstable angina pectoris.
Topics: Angina, Unstable; Clopidogrel; Humans; Neutropenia; Platelet Aggregation Inhibitors; Ticlopidine | 2000 |
Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention.
Topics: Angina, Unstable; Angioplasty; Anticoagulants; Aspirin; Cardiovascular Diseases; Clinical Trials as | 2000 |
[Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clinical Trials as Topic; | 2001 |
Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibod | 2001 |
Clopidogrel in invasive management of non-ST-elevation ACS.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Humans; My | 2001 |
[Antithrombotic therapy of unstable angina pectoris].
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardi | 1998 |
[Clopidogrel in acute coronary syndromes with non-ST elevation. Clinical implications of the CURE trial].
Topics: Angina, Unstable; Aspirin; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hu | 2001 |
Unstable angina guidelines expand use of clopidogrel, enoxaparin.
Topics: Angina, Unstable; Clopidogrel; Enoxaparin; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibit | 2002 |